Document:

EX-10.4

 Exhibit 10.4 

EXECUTION VERSION 
  

 
 AMENDED AND RESTATED 

REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT 

BY AND AMONG 
 DRAGONEER GROWTH
OPPORTUNITIES CORP. 
 AND 
 THE
STOCKHOLDERS PARTY HERETO 
 DATED AS OF FEBRUARY 2, 2021 
  

 

 TABLE OF CONTENTS 

 

							
	Article I EFFECTIVENESS	  	 	2	
			
	        1.1.	 	Effectiveness	  	 	2	
		
	Article II DEFINITIONS	  	 	2	
			
	        2.1.	 	Definitions	  	 	2	
			
	        2.2.	 	Other Interpretive Provisions	  	 	10	
		
	Article III REGISTRATION RIGHTS	  	 	11	
			
	        3.1.	 	Demand Registration	  	 	11	
			
	        3.2.	 	Shelf Registration	  	 	13	
			
	        3.3.	 	Piggyback Registration	  	 	16	
			
	        3.4.	 	Lock-Up Agreements	  	 	17	
			
	        3.5.	 	Registration Procedures	  	 	19	
			
	        3.6.	 	Underwritten Offerings	  	 	24	
			
	        3.7.	 	No Inconsistent Agreements; Additional Rights	  	 	25	
			
	        3.8.	 	Registration Expenses	  	 	25	
			
	        3.9.	 	Indemnification	  	 	26	
			
	        3.10.	 	Rules 144 and 144A and Regulation S	  	 	29	
			
	        3.11.	 	Existing Registration Statements	  	 	29	
		
	Article IV SHAREHOLDER RIGHTS AND RELATED PROVISIONS	  	 	30	
			
	        4.1.	 	Board of Directors	  	 	30	
			
	        4.2.	 	Board Committees	  	 	33	
			
	        4.3.	 	Subsidiary Boards and Committees	  	 	33	
			
	        4.4.	 	Director Expenses	  	 	33	
			
	        4.5.	 	Directors’ and Officers’ Insurance	  	 	33	
			
	        4.6.	 	Confidentiality	  	 	34	
			
	        4.7.	 	Other Business Opportunities	  	 	35	
			
	        4.8.	 	Other Business Activities of Sponsor Investors	  	 	36	
			
	        4.9.	 	Amendment of the Business Combination Agreement	  	 	36	
		
	Article V MISCELLANEOUS	  	 	36	
			
	        5.1.	 	Authority; Effect	  	 	36	
			
	        5.2.	 	Notices	  	 	37	
			
	        5.3.	 	Termination and Effect of Termination	  	 	37	

  
 - i - 

							
	         5.4.
	 	 Permitted Transferees
	  	 	38	
			
	         5.5.
	 	 Legend Removal
	  	 	38	
			
	         5.6.
	 	 Remedies
	  	 	39	
			
	         5.7.
	 	 Amendments
	  	 	39	
			
	         5.8.
	 	 Governing Law
	  	 	39	
			
	         5.9.
	 	 Consent to Jurisdiction; Venue; Service
	  	 	39	
			
	         5.10.
	 	 WAIVER OF JURY TRIAL
	  	 	40	
			
	         5.11.
	 	 Merger; Binding Effect; Assignment
	  	 	40	
			
	         5.12.
	 	 Counterparts
	  	 	40	
			
	         5.13.
	 	 Severability
	  	 	41	
			
	         5.14.
	 	 No Recourse
	  	 	41	

  
 - ii - 

 This AMENDED AND RESTATED REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (as it may be
amended, restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of February 2, 2021, is made by and among: 

i.    Dragoneer Growth Opportunities Corp., a Cayman Islands exempted company (the “Company”); 

ii.    each Person executing this Agreement and listed as a “Sponsor Investor” on Schedule A hereto
(collectively, together with their respective Permitted Transferees that become parties hereto, the “Sponsor Investors”); and 

iii.    each Person executing this Agreement and listed as an “Individual Investor” on Schedule B
hereto, as it may be amended from time to time (collectively, together with their respective Permitted Transferees that become parties hereto, the “Individual Investors”, and collectively with the Sponsor Investors, the
“Investors”). 
 RECITALS 

WHEREAS, the Company, Dragoneer Growth Opportunities Holdings, a Cayman Islands limited liability company (the “Dragoneer
Sponsor”), Sarah J. Friar, Douglas Merritt, David D. Ossip, Gokul Rajaram and Jay Simons (the “Dragoneer Directors”) are parties to that certain Registration and Shareholder Rights Agreement, dated as of August 13,
2020 (the “Prior Agreement”); 
 WHEREAS, the Company, Chariot Opportunity Merger Sub, Inc. (“Chariot Merger
Sub”) and Cypress Holdings, Inc., a Delaware corporation (“Chariot Target”), have entered into that certain Business Combination Agreement, dated as of February 2, 2021 (as amended, restated, supplemented or otherwise
modified from time to time, the “Business Combination Agreement”), pursuant to which, among other things, Chariot Merger Sub will merge with and into Chariot Target, with Chariot Target as the surviving company in the merger, and,
as a result of such merger, Chariot Target will become a wholly owned subsidiary of the Company; and 
 WHEREAS, in connection with the
transactions contemplated by the Business Combination Agreement, the Company and the other parties hereto desire to amend and restate the Prior Agreement in its entirety and to enter into this Agreement and, in the case of the parties to the Prior
Agreement, to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement. 

 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements
set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the other parties to this Agreement, intending to be legally bound, hereby agree to amend and restate the Prior
Agreement in its entirety as set forth herein, and the parties hereto further agree as follows: 
 ARTICLE I 

EFFECTIVENESS 

1.1.    Effectiveness. This Agreement shall become effective upon the Closing. 

ARTICLE II 
 DEFINITIONS

 2.1.    Definitions. 

2.1.1.    Capitalized terms used and not otherwise defined in Section 2.1.2 or elsewhere in this Agreement
shall have the meanings ascribed to such terms in the Business Combination Agreement. 
 2.1.2.    The following terms
shall have the meanings ascribed to them in this Section 2.1.2 for purposes of this Agreement: 
 “Advent
Post-Closing Shareholders” means Cypress Investor Holdings, L.P., GPE VIII CCC Co-Investment (Delaware) Limited Partnership and Advent International GPE VIII-C
Limited Partnership and their respective Permitted Transferees. 
 “Adverse Disclosure” means public disclosure of material
non-public information that, in the good faith judgment of the Board: (a) would be required to be made in any Registration Statement filed with the SEC by the Company so that such Registration Statement,
from and after its effective date, does not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (b) would not be required to
be made at such time but for the filing, effectiveness or continued use of such Registration Statement; and (c) the Company has a bona fide business purpose for not disclosing publicly. 

“Affiliate” means, (a) with respect to any specified Person that is not a natural person, (i) any other Person
which directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with, such specified Person, and (ii) any corporation, trust, limited liability company, general or limited partnership or
other entity advised or managed by, or under common control or management with, such Person (for the purposes of this definition, “control” (including, with correlative meanings, the terms “controlling,” “controlled by”
and “under common control with”), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership
of voting securities, by agreement or otherwise) and (b) with respect to any specified natural person, any Member of the Immediate Family of such specified natural person, or any Person that is, directly or indirectly, controlled by such
specified natural person; provided that the Company and each of its subsidiaries shall be deemed not to be Affiliates of any Investor. 

“Agreement” shall have the meaning set forth in the preamble. 

  
 - 2 - 

 “Board” means the board of directors of the Company. 

“Business Day” means a day, other than a Saturday or Sunday, on which commercial banks in New York, New York and Chicago,
Illinois are open for the general transaction of business. 
 “Business Combination Agreement” shall have the meaning set
forth in the preamble. 
 “Bylaws” means the bylaws of the Company, as amended, restated, supplemented or otherwise
modified and in effect from time to time. 
 “Certificate” means the certificate of incorporation of the Company, as
amended, restated, supplemented or otherwise modified and in effect from time to time, including any certificate of designation, correction or amendment filed with the Secretary of State of the State of Delaware. 

“Chariot Target” shall have the meaning set forth in the preamble. 

“Charitable Gifting Event” means any Transfer by a holder of Registrable Securities, or any subsequent Transfer by such
holder’s members, partners or other employees, in connection with a bona fide gift to any Charitable Organization made on the date of, but prior to, the execution of the underwriting agreement entered into in connection with any Underwritten
Public Offering. 
 “Charitable Organization” means a charitable organization as described by Section 501(c)(3) of the
Internal Revenue Code of 1986, as in effect from time to time. 
 “Common Stock” means the common stock of the Company, par
value $0.0001 per share. 
 “Company Indemnitees” shall have the meaning set forth in
Section 3.9.5. 
 “Confidential Information” shall have the meaning set forth in
Section 4.6. 
 “Convertible Securities” means any evidence of indebtedness, shares of stock
(other than Common Stock) or other securities (other than Options and Warrants) which are directly or indirectly convertible into or exchangeable or exercisable for shares of Common Stock. 

“Demand Notice” shall have the meaning set forth in Section 3.1.3. 

“Demand Registration” shall have the meaning set forth in Section 3.1.1.1. 

“Demand Registration Request” shall have the meaning set forth in Section 3.1.1.1. 

“Demand Registration Statement” shall have the meaning set forth in Section 3.1.1.3. 

“Demand Suspension” shall have the meaning set forth in Section 3.1.6. 

“Director” means any director of the Company. 

“Dragoneer Post-Closing Shareholders” means Dragoneer Sponsor, the Dragoneer Directors and their respective Permitted
Transferees. 

  
 - 3 - 

 “Dragoneer Step-Down Date” means the first annual meeting of stockholders
of the Company to be held following the Closing Date. 
 “Equivalent Shares” means, at any date of determination,
(a) as to any outstanding shares of Common Stock, such number of shares of Common Stock and (b) as to any outstanding Options, Warrants or Convertible Securities which constitute Shares, the maximum number of shares of Common Stock for
which or into which such Options, Warrants or Convertible Securities may at the date of determination be exercised, converted or exchanged (or which will become exercisable, convertible or exchangeable on or prior to, or by reason of, the
transaction or circumstance in connection with which the number of Equivalent Shares is to be determined) but excluding any shares of restricted stock or Options that are not then vested or will not become vested on or prior to, or by reason of, the
transaction or circumstance in connection with which the number of Equivalent Shares is to be determined. 
 “Exchange Act”
means the Securities Exchange Act of 1934, as amended, and any successor thereto, and any rules and regulations promulgated thereunder, all as the same shall be in effect from time to time. 

“External Party” shall have the meaning set forth in Section 4.7. 

“FINRA” means the Financial Industry Regulatory Authority. 

“Final Advent Step-Down Date” means the date on which the Advent Post-Closing Shareholders collectively first cease to own
beneficially or of record a number of shares of Common Stock (or other securities of the Company into which such shares of Common Stock are converted or for which such shares of Common Stock are exchanged) constituting at least 10% of the number of
shares of Common Stock owned by the Advent Post-Closing Shareholders collectively immediately after the Closing (or other securities of the Company into which such shares of Common Stock are converted or for which such shares of Common Stock are
exchanged). 
 “First Advent Step-Down Date” means the date on which the Advent Post-Closing Shareholders collectively
first cease to own beneficially or of record a number of shares of Common Stock (or other securities of the Company into which such shares of Common Stock are converted or for which such shares of Common Stock are exchanged) constituting at least
50% of the number of shares of Common Stock owned by the Advent Post-Closing Shareholders collectively immediately after the Closing (or other securities of the Company into which such shares of Common Stock are converted or for which such shares of
Common Stock are exchanged). 
 “Fund Indemnitor” shall have the meaning set forth in
Section 4.5. 
 “Holders” means, as of any determination time, Investors who hold Registrable
Securities under this Agreement. 
 “Independent Director” means a Director who qualifies as “independent” under
Section 303A.02 of the NYSE Listed Company Manual (or any successor or replacement provision). 
 “Individual
Investor” shall have the meaning set forth in the preamble. 

  
 - 4 - 

 “Individual Investor Shares” means all shares of Common Stock originally
issued to, or issued with respect to securities of the Company originally issued to, or held by, an Individual Investor, whenever issued, including all shares of Common Stock issued upon the exercise, conversion or exchange of any Options, Warrants
or Convertible Securities. 
 “Investor” shall have the meaning set forth in the preamble. 

“Issuer Free Writing Prospectus” means an issuer free writing prospectus, as defined in Rule 433 under the Securities Act,
relating to an offer of the Registrable Securities. 
 “Lock-Up” shall have the
meaning set forth in Section 3.4.1. 
 “Lock-Up Period”
shall have the meaning set forth in Section 3.4.1. 
 “Lock-Up
Release Condition” means that the closing price of the Common Stock has been greater than or equal to $12.00 per share (as adjusted for share subdivisions, share capitalizations, share consolidations, reorganizations, recapitalizations and
the like) measured using the daily closing price for any 20 trading days within a 30-trading day period commencing at least 120 days after the Closing Date. 

“Loss” shall have the meaning set forth in Section 3.9.1. 

“Majority Sponsor Investors” means, as of any date, the holders holding a majority of the Sponsor Investor Shares outstanding
on such date. 
 “Member of the Immediate Family” means, with respect to any Person who is an individual, (a) each
parent, spouse (but not including a former spouse or a spouse from whom such Person is legally separated) or child (including those adopted) of such individual and (b) each trustee, solely in his or her capacity as trustee, for a trust naming
only one or more of the Persons listed in sub-clause (a) as beneficiaries. 

“Necessary Action” means all actions (to the extent that such actions are within the Company’s control and are not
prohibited by applicable law, regulation or NYSE rules or, in the case of any action that requires action by a Director, inconsistent with any fiduciary duties that such Director has in such capacity which have not been validly waived) necessary or
advisable to cause a specified result, including, as applicable (and to the extent that such actions are within the Company’s control and are not prohibited by applicable law, regulation or NYSE rules or, in the case of any action by a
Director, inconsistent with any fiduciary duties that such Director has in such capacity which have not been validly waived), (a) calling special meetings of the Board or the stockholders of the Company, (b) recommending (whether to the Board,
to the stockholders of the Company or otherwise) or nominating a particular individual for election or appointment as a Director and, if applicable, appointing such individual as a Director, (c) including such individual as a nominee for
Director in the Company’s proxy materials and form of proxy and soliciting proxies from stockholders of the Company in favor of the election of such individual in a manner no less rigorous and favorable than the manner in which the Company
supports its other nominees, (d) causing the Directors to be present for quorum purposes at any relevant meeting of the Board or any committee thereof and to vote in favor of or provide written consent with respect to any proposed action or
matter in furtherance of such specified result and to vote against or withhold 

  
 - 5 - 

 
written consent with respect to any proposed action or matter inconsistent with such specified result, (e) executing and delivering agreements and instruments, (f) making, or causing to
be made, filings with the SEC or any other appropriate Person and (g) not taking any action that would prevent, impair or delay the achievement of the specified result. 

“New Securities” means any capital stock of the Company, including the Common Stock, whether now authorized or not, and
rights, options or warrants to purchase such capital stock, and securities of any type whatsoever (including convertible debt securities) that are, or may become, convertible into or exchangeable or exercisable for capital stock of the Company;
provided that the term “New Securities” does not include (a) capital stock or rights, options or warrants to acquire capital stock of the Company, including stock options, restricted stock units or restricted stock awards,
issued to existing or prospective employees, consultants, officers or directors of the Company or any subsidiary, or which have been reserved for issuance, pursuant to equity incentive, employee stock option, employee stock purchase, stock bonus,
inducement grant or other similar compensation plan or arrangement approved by the Board or, if applicable, a duly authorized committee thereof, (b) securities of the Company issued to all then-existing stockholders in connection with any stock
split, stock dividend, reclassification, recapitalization or reorganization of the Company, so long as such transaction is effected pro rata among holders of such securities, (c) securities of the Company issued upon the exercise of warrants
that are outstanding as of the date of this Agreement, (d) securities of the Company issued in connection with a transaction of the type described in Rule 145 under the Securities Act and (e) securities of the Company issued in
connection with a bona fide joint venture, collaboration, licensing, development, marketing, distribution or similar commercial agreement, any merger or acquisition of the business, securities or assets of another Person or any credit or loan
agreement or arrangement, in each case, with an unaffiliated third party pursuant to an arm’s length transaction other than for cash that is approved by the Board or, if applicable, a duly authorized committee thereof. 

“Non-Underwritten Offering” means any Public Offering other than an Underwritten
Public Offering. 
 “NYSE” means the New York Stock Exchange. 

“Oak Hill Post-Closing Shareholders” means OH Cypress Aggregator, L.P. and its Permitted Transferees. 

“Oak Hill Step-Down Date” means the date on which the Oak Hill Post-Closing Shareholders collectively first cease to own
beneficially or of record a number of shares of Common Stock (or other securities of the Company into which such shares of Common Stock are converted or for which such shares of Common Stock are exchanged) constituting at least 60% of the number of
shares of Common Stock owned by the Oak Hill Post-Closing Shareholders collectively immediately after the Closing (or other securities of the Company into which such shares of Common Stock are converted or for which such shares of Common Stock are
exchanged). 
 “Options” means any options to subscribe for, purchase or otherwise directly acquire Common Stock. 

  
 - 6 - 

 “Participation Conditions” shall have the meaning set forth in
Section 3.2.5.2. 
 “Permitted Transferee” means any Affiliate of an Investor. 

“Person” means any individual, partnership, corporation, company, association, trust, joint venture, limited liability
company, unincorporated organization, entity or division, or any government, governmental department or agency or political subdivision thereof. 

“Piggyback Notice” shall have the meaning set forth in Section 3.3.1. 

“Piggyback Registration” shall have the meaning set forth in Section 3.3.1. 

“PIPE Registration Statement” means the Registration Statement required to be filed by the Company pursuant to the terms of
the Other Investor Subscription Agreements. 
 “Potential Takedown Participant” shall have the meaning set forth in
Section 3.2.5.2. 
 “Prior Agreement” shall have the meaning set forth in the preamble. 

“Pro Rata Portion” means, with respect to each Holder requesting that its shares be registered or sold in an Underwritten
Public Offering, a number of such shares equal to the aggregate number of Registrable Securities to be registered or sold (excluding any shares to be registered or sold for the account of the Company) multiplied by a fraction, the numerator of which
is the aggregate number of Registrable Securities held by such Holder, and the denominator of which is the aggregate number of Registrable Securities held by all Holders requesting that their Registrable Securities be registered or sold. 

“Prospectus” means (a) the prospectus included in any Registration Statement, all amendments and supplements to such
prospectus, including post-effective amendments and supplements, and all other material incorporated by reference in such prospectus, and (b) any Issuer Free Writing Prospectus. 

“Public Offering” means the offer and sale of Registrable Securities for cash pursuant to an effective Registration Statement
under the Securities Act (other than a Registration Statement on Form S-4 or Form S-8 or any successor form). 

“Registrable Securities” means (a) all shares of Common Stock that are not then subject to forfeiture to the Company,
(b) all shares of Common Stock issuable upon exercise, conversion or exchange of any option, warrant or convertible security not then subject to vesting or forfeiture to the Company, (c) all Warrants and (d) all shares of Common Stock
directly or indirectly issued or then issuable with respect to the securities referred to in clauses (a), (b) or (c) above by way of a stock dividend or stock split, or in connection with a combination of shares, recapitalization, merger,
consolidation or other reorganization. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when (i) a Registration Statement with respect to the sale of such securities shall have become
effective under the Securities Act and such securities shall have been disposed of in accordance with such Registration Statement, (ii) such securities shall have been Transferred pursuant to Rule 144 or (iii) such securities shall have
ceased to be outstanding. 

  
 - 7 - 

 “Registration” means registration under the Securities Act of the offer and
sale to the public of any Registrable Securities under a Registration Statement. The terms “register”, “registered” and “registering” shall have correlative meanings. 

“Registration Expenses” shall have the meaning set forth in Section 3.8. 

“Registration Statement” means any registration statement of the Company filed with, or to be filed with, the SEC under the
Securities Act, including the related Prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by
reference in such registration statement other than a registration statement (and related Prospectus) filed on Form S-4 or Form S-8 or any successor form thereto. 

“Representatives” means, with respect to any Person, any of such Person’s officers, directors, employees, agents,
attorneys, accountants, actuaries, consultants, equity financing partners or financial advisors or other Person associated with, or acting on behalf of, such Person. 

“Rule 144” means Rule 144 under the Securities Act (or any successor rule). 

“SEC” means the Securities and Exchange Commission or any successor agency having jurisdiction under the Securities Act. 

“Second Advent Step-Down Date” means the date on which the Advent Post-Closing Shareholders collectively first cease to own
beneficially or of record a number of shares of Common Stock (or other securities of the Company into which such shares of Common Stock are converted or for which such shares of Common Stock are exchanged) constituting at least 25% of the number of
shares of Common Stock owned by the Advent Post-Closing Shareholders collectively immediately after the Closing (or other securities of the Company into which such shares of Common Stock are converted or for which such shares of Common Stock are
exchanged). 
 “Securities Act” means the Securities Act of 1933, as amended, and any successor thereto, and any rules and
regulations promulgated thereunder, all as the same shall be in effect from time to time. 
 “Shares” means all Sponsor
Investor Shares and Individual Investor Shares. 
 “Shelf Period” shall have the meaning set forth in
Section 3.2.3. 
 “Shelf Registration” shall have the meaning set forth in
Section 3.2.1.1. 
 “Shelf Registration Notice” shall have the meaning set forth in
Section 3.2.2. 
 “Shelf Registration Request” shall have the meaning set forth in
Section 3.2.1.1. 
 “Shelf Registration Statement” shall have the meaning set forth in
Section 3.2.1.1. 
 “Shelf Suspension” shall have the meaning set forth in
Section 3.2.4. 

  
 - 8 - 

 “Shelf Takedown Notice” shall have the meaning set forth in
Section 3.2.5.2. 
 “Shelf Takedown Request” shall have the meaning set forth in
Section 3.2.5.1. 
 “Sponsor Holders” means, as of any determination time, Sponsor
Investors who hold Registrable Securities under this Agreement. 
 “Sponsor Investor” shall have the meaning set
forth in the preamble, provided that, upon written notice to the Company, the Dragoneer Sponsor may irrevocably elect to cease to be a Sponsor Investor for purposes of Section 3 of this Agreement, but shall continue to be a
Holder for all purposes under this Agreement for as long as the Dragoneer Sponsor continues to hold Registrable Securities. 

“Sponsor Investor Shares” means all shares of Common Stock originally issued to, or issued with respect to securities
of the Company originally issued to, or held by, a Sponsor Investor, whenever issued, including all shares of Common Stock issued upon the exercise, conversion or exchange of any Options, Warrants or Convertible Securities. 

“Strategic Investor” shall have the meaning set forth in Section 4.8. 

“TCV Post-Closing Shareholders” means TCV IX, L.P., TCV IX (A), L.P., TCV IX (B), L.P. and TCV Member Fund, L.P. and any of
their respective Permitted Transferees. 
 “TCV Step-Down Date” means the date on which the TCV Post-Closing Shareholders
collectively first cease to own beneficially or of record a number of shares of Common Stock (or other securities of the Company into which such shares of Common Stock are converted or for which such shares of Common Stock are exchanged)
constituting at least 60% of the number of shares of Common Stock owned by the TCV Post-Closing Shareholders collectively immediately after the Closing (or other securities of the Company into which such shares of Common Stock are converted or for
which such shares of Common Stock are exchanged). 
 “Transaction Agreements” shall have the meaning set forth in
Section 4.8. 
 “Transfer” means, with respect to any Registrable Security, any interest therein,
or any other securities or equity interests relating thereto, a direct or indirect transfer, sale, exchange, assignment, pledge, hypothecation or other encumbrance or other disposition thereof, including the grant of an option or other right,
whether directly or indirectly, whether voluntarily, involuntarily, by operation of law, pursuant to judicial process or otherwise. “Transferred” shall have a correlative meaning. 

“Underwritten Public Offering” means an underwritten Public Offering, including any bought deal or block sale to a financial
institution conducted as an underwritten Public Offering. 
 “Underwritten Shelf Takedown” means an Underwritten Public
Offering pursuant to an effective Shelf Registration Statement. 
 “Warrants” means any warrants to subscribe for, purchase
or otherwise directly acquire Common Stock. 

  
 - 9 - 

 “WKSI” means any Securities Act registrant that is a well-known seasoned
issuer as defined in Rule 405 under the Securities Act at the most recent eligibility determination date specified in paragraph (2) of that definition. 

2.2.    Other Interpretive Provisions. 

(a)    The meanings of defined terms are equally applicable to the singular and plural forms of the defined terms. 

(b)    The words “hereof”, “herein”, “hereunder” and similar words refer to this Agreement
as a whole and not to any particular provision of this Agreement; and any subsection and section references are to this Agreement unless otherwise specified. 

(c)    The term “including” is not limiting and means “including without limitation.” 

(d)    The captions and headings of this Agreement are for convenience of reference only and shall not affect the
interpretation of this Agreement. 
 (e)    Whenever the context requires, any pronouns used herein shall include the
corresponding masculine, feminine or neuter forms. 
 (f)    The words “any” and “or” are not
exclusive. 
 (g)    The word “extent” in the phrase “to the extent” means the degree to which a
subject or other thing extends and does not mean simply “if.” 
 (h)    “Writing”,
“written” and comparable terms refer to printing, typing and other means of reproducing words (including in email or other electronic media) in a visible form. 

(i)    Unless the context requires otherwise, references to any statute, regulation or rule shall be deemed to refer to
such statute, regulation or rule as amended or supplemented from time to time, including through the promulgation of rules or regulations thereunder, and references to any agreement or instrument shall be deemed to refer to such agreement or
instrument and all schedules, exhibits and annexes thereto, in each case, as amended, restated, supplemented or otherwise modified from time to time. 

(j)    Unless otherwise specified, the reference date for purposes of calculating any period shall be excluded from such
calculation, but any period “from” or “through” a specified date shall commence or end, as applicable, on such specified date; provided that, in the event that any period would end on a day that is not a Business Day, such
period shall be extended until, and shall instead end on, the next Business Day following the day on which such period would otherwise end. 

  
 - 10 - 

 ARTICLE III 

REGISTRATION RIGHTS 
 The
Company will perform and comply, and cause each of its subsidiaries to perform and comply, with such of the following provisions as are applicable to it. Each Holder will perform and comply with such of the following provisions as are applicable to
such Holder. 
 3.1.    Demand Registration. 

3.1.1.    Request for Demand Registration. 

3.1.1.1.    At (a) any time after the Closing Date, any Sponsor Holder (other than the Oak Hill Post-Closing
Shareholders and the TCV Post-Closing Shareholders) or (b) any time after the date that is twelve (12) months following the Closing Date, the Oak Hill Post-Closing Shareholders collectively and the TCV Post-Closing Shareholders
collectively shall have the right to make one or more written requests from time to time (a “Demand Registration Request”) to the Company for Registration of all or part of the Registrable Securities held by such Sponsor Holder. Any
such Registration pursuant to a Demand Registration Request shall hereinafter be referred to as a “Demand Registration.” 

3.1.1.2.    Each Demand Registration Request shall specify (x) the kind and aggregate amount of Registrable
Securities to be registered, and (y) the intended method or methods of disposition thereof including pursuant to an Underwritten Public Offering. 

3.1.1.3.    Upon receipt of a Demand Registration Request, the Company shall as promptly as practicable file a
Registration Statement (a “Demand Registration Statement”) relating to such Demand Registration, and use its reasonable best efforts to cause such Demand Registration Statement to be promptly declared effective under the Securities
Act. 
 3.1.2.    Limitation on Demand Registrations. The Company shall not be obligated to take any action to
effect any Demand Registration if a Demand Registration or Piggyback Registration was declared effective or an Underwritten Shelf Takedown was consummated within the preceding ninety (90) days (unless otherwise consented to by the Company). The
Oak Hill Post-Closing Shareholders collectively and the TCV Post-Closing Shareholders collectively each shall have the right to make one (1) Demand Registration. 

3.1.3.    Demand Notice. Promptly upon receipt of a Demand Registration Request pursuant to
Section 3.1.1 (but in no event more than two (2) Business Days thereafter), the Company shall deliver a written notice (a “Demand Notice”) of any such Demand Registration Request to all other Sponsor
Holders and the Demand Notice shall offer each such Sponsor Holder the opportunity to include in the Demand Registration that number of Registrable Securities as each such Sponsor Holder may request in writing. Subject to
Section 3.1.7, the Company shall include in the Demand Registration all such Registrable Securities with respect to which the Company has received written requests for inclusion therein within three (3) Business Days
after the date that the Demand Notice was delivered. 

  
 - 11 - 

 3.1.4.    Demand Withdrawal. Any Sponsor Holder that has
requested its Registrable Securities be included in a Demand Registration pursuant to Section 3.1.1 or Section 3.1.3 may withdraw all or any portion of its Registrable Securities included in a
Demand Registration from such Demand Registration at any time prior to the effectiveness of the applicable Demand Registration Statement. Upon receipt of a notice to such effect with respect to all of the Registrable Securities included in such
Demand Registration, the Company shall cease all efforts to secure effectiveness of the applicable Demand Registration Statement. 

3.1.5.    Effective Registration. The Company shall use reasonable best efforts to cause the applicable Demand
Registration Statement to become effective promptly after receipt of a Demand Registration Request and remain effective for not less than one hundred eighty (180) days (or such shorter period as will terminate when all Registrable Securities
covered by such Demand Registration Statement have been sold or withdrawn), or, if such Demand Registration Statement relates to an Underwritten Public Offering, such longer period as in the opinion of counsel for the underwriter or underwriters a
Prospectus is required by law to be delivered in connection with sales of Registrable Securities by an underwriter or dealer. 

3.1.6.    Delay in Filing; Suspension of Registration. If the filing, initial effectiveness or continued use of a
Demand Registration Statement at any time would require the Company to make an Adverse Disclosure, the Company may, upon giving prompt written notice of such action to the Sponsor Holders, delay the filing or initial effectiveness of, or suspend use
of, the Demand Registration Statement (a “Demand Suspension”); provided, however, that the Company shall not be permitted to exercise a Demand Suspension more than one (1) time during any twelve (12)-month period
or for a total period of greater than sixty (60) days; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such sixty
(60)-day period, other than pursuant to a registration relating to the sale or grant of securities to employees or directors of the Company or a subsidiary pursuant to a stock option, stock purchase, equity
incentive or similar plan; a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or a registration in
which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. In the case of a Demand Suspension, the Sponsor Holders agree to suspend use of the applicable Prospectus in
connection with any sale or purchase, or offer to sell or purchase, Registrable Securities, upon receipt of the notice referred to above. The Company shall immediately notify the Sponsor Holders in writing upon the termination of any Demand
Suspension, amend or supplement the Prospectus, if necessary, so it does not contain any untrue statement of a material fact or any omission of a material fact required to be stated therein or necessary to make the statements therein not misleading
and furnish to the Sponsor Holders such numbers of copies of the Prospectus as so amended or supplemented as the Sponsor Holders may reasonably request. The Company shall, if necessary, supplement or amend the Demand Registration Statement, if
required by the registration form used by the Company for the Demand Registration or by the instructions applicable to such registration form or by the Securities Act or the rules or regulations promulgated thereunder or as may reasonably be
requested by the Sponsor Holders holding a majority of Registrable Securities that are included in such Demand Registration Statement. 

  
 - 12 - 

 3.1.7.    Priority of Securities Registered Pursuant to Demand
Registrations. If the managing underwriter or underwriters of a proposed Underwritten Public Offering of the Registrable Securities included in a Demand Registration advise the Company in writing that, in its or their opinion, the number of
securities requested to be included in such Demand Registration exceeds the number that can be sold in such offering without being likely to have an adverse effect on the price, timing or distribution of the securities offered or the market for the
securities offered, then the securities to be included in such Registration shall be, in the case of any Demand Registration, (x) first, allocated to each Sponsor Holder that has requested to participate in such Demand Registration an amount
equal to the lesser of (i) the number of such Registrable Securities requested to be registered or sold by such Sponsor Holder, and (ii) a number of such shares equal to such Sponsor Holder’s Pro Rata Portion, and (y) second, and
only if all the securities referred to in clause (x) have been included, the number of other securities that, in the opinion of such managing underwriter or underwriters can be sold without having such adverse effect. 

3.2.    Shelf Registration. 

3.2.1.    Request for Shelf Registration. 

3.2.1.1.    At any time after the Closing Date, upon the written request of any Sponsor Holder (other than the Oak Hill
Post-Closing Shareholders and the TCV Post-Closing Shareholders in the case of an underwritten offering during the first twelve (12) months following the Closing Date) from time to time (a “Shelf Registration Request”), the
Company shall promptly file with the SEC a shelf Registration Statement pursuant to Rule 415 under the Securities Act (“Shelf Registration Statement”) relating to the offer and sale of Registrable Securities by any Sponsor Holders
thereof from time to time providing for any method or combination of methods of distribution legally available to any Sponsor Holder, and the Company shall use its reasonable best efforts to cause such Shelf Registration Statement to promptly become
effective under the Securities Act. Any such Registration pursuant to a Shelf Registration Request shall hereinafter be referred to as a “Shelf Registration.” The Advent Post-Closing Shareholders shall be deemed to have given a
Shelf Registration Request as of the date of this Agreement with respect to their Registrable Securities, and the Company may satisfy this Shelf Registration Request by including such Registrable Securities on the PIPE Registration Statement;
provided, however, that the inclusion of such Registrable Securities on the PIPE Registration Statement shall not relieve the Company of any of its other obligations with respect to such Registrable Securities pursuant to this
Section 3.2 or otherwise; provided, further, that the Company shall not be required to deliver a Shelf Registration Notice to any other Holder as a result of such Shelf Registration Request. Notwithstanding
anything to the contrary set forth herein, all of the Registrable Securities held by the Investors immediately following the Closing shall be included in the initial Shelf Registration Statement filed by the Company following the Closing (including,
for the avoidance of doubt, any Registration Statement filed in connection with the PIPE Financing), which Registration Statement shall include a plan of distribution reasonably acceptable to the Sponsor Investors (including the Dragoneer
Post-Closing Shareholders, if not then a Sponsor Investor) in order to facilitate Non-Underwritten Offerings; provided that, if the SEC requests that any Investor be identified as a statutory
underwriter in such Registration Statement, such Investor will have an opportunity to withdraw its Shares from such Registration Statement and, as promptly as practicable after being permitted to register additional Registrable Securities under Rule
415 under the Securities Act, the Company shall amend such Registration Statement or file a new Registration Statement to register 

  
 - 13 - 

 
such additional Registrable Securities and cause such amendment or new Registration Statement to become effective as promptly as practicable. For the avoidance of doubt, any Registration
Statement so filed shall be deemed a Shelf Registration for purposes of this Agreement. 
 3.2.1.2.    If on the date of
the Shelf Registration Request the Company is a WKSI, then the Shelf Registration Request may request Registration of an unspecified amount of Registrable Securities to be sold by unspecified Holders. If on the date of the Shelf Registration Request
the Company is not a WKSI, then the Shelf Registration Request shall specify the aggregate amount of Registrable Securities to be registered. The Company shall provide to any Sponsor Holder the information necessary to determine the Company’s
status as a WKSI upon such Sponsor Holder’s request. 
 3.2.2.    Shelf Registration Notice. Promptly upon
receipt of a Shelf Registration Request (but in no event more than two (2) Business Days thereafter (or such shorter period as may be reasonably requested in connection with an underwritten “block trade”)), the Company shall deliver a
written notice (a “Shelf Registration Notice”) of any such request to all other Holders, which notice shall specify, if applicable, the amount of Registrable Securities to be registered, and the Shelf Registration Notice shall offer
each such Holder the opportunity to include in the Shelf Registration that number of Registrable Securities as each such Sponsor Holder may request in writing; provided that, in the case of an underwritten “block trade,” the Company
shall only deliver the Shelf Registration Notice to Sponsor Holders. The Company shall include in such Shelf Registration all such Registrable Securities with respect to which the Company has received written requests for inclusion therein within
three (3) Business Days (or such shorter period as may be reasonably requested in connection with an underwritten “block trade”) after the date that the Shelf Registration Notice has been delivered. 

3.2.3.    Continued Effectiveness. The Company shall use its reasonable best efforts to keep such Shelf
Registration Statement continuously effective under the Securities Act in order to permit the Prospectus forming part of the Shelf Registration Statement to be usable by Sponsor Holders until the earlier of: (i) the date as of which all
Registrable Securities have been sold pursuant to the Shelf Registration Statement or another Registration Statement filed under the Securities Act (but in no event prior to the applicable period referred to in Section 4(a)(3) of the Securities
Act and Rule 174 thereunder); and (ii) the date as of which no Sponsor Holder holds Registrable Securities (such period of continuous effectiveness, the “Shelf Period”). Subject to Section 3.2.4, the
Company shall be deemed not to have used its reasonable best efforts to keep the Shelf Registration Statement effective during the Shelf Period if the Company voluntarily takes any action or omits to take any action that would result in Sponsor
Holders of the Registrable Securities covered thereby not being able to offer and sell any Registrable Securities pursuant to such Shelf Registration Statement during the Shelf Period, unless such action or omission is required by applicable law.

 3.2.4.    Suspension of Registration. If the continued use of such Shelf Registration Statement at any time
would require the Company to make an Adverse Disclosure, the Company may, upon giving prompt written notice of such action to the Holders, suspend use of the Shelf Registration Statement (a “Shelf Suspension”); provided,
however, that the Company shall not be permitted to exercise a Shelf Suspension more than one (1) time during any twelve (12)-month period or for a total period of greater than sixty (60) days. In the case of a Shelf Suspension, the

  
 - 14 - 

 
Holders agree to suspend use of the applicable Prospectus in connection with any sale or purchase of, or offer to sell or purchase, Registrable Securities, upon receipt of the notice referred to
above. The Company shall immediately notify the Holders in writing upon the termination of any Shelf Suspension, amend or supplement the Prospectus, if necessary, so it does not contain any untrue statement of a material fact or any omission of a
material fact required to be stated therein or necessary to make the statements therein not misleading and furnish to the Holders such numbers of copies of the Prospectus as so amended or supplemented as the Holders may reasonably request. The
Company shall, if necessary, supplement or amend the Shelf Registration Statement, if required by the registration form used by the Company for the Shelf Registration Statement or by the instructions applicable to such registration form or by the
Securities Act or the rules or regulations promulgated thereunder or as may reasonably be requested by the Holders holding a majority of Registrable Securities that are included in such Shelf Registration Statement. 

3.2.5.    Shelf Takedown. 

3.2.5.1.    At any time the Company has an effective Shelf Registration Statement with respect to a Sponsor Holder’s
Registrable Securities, by notice to the Company specifying the intended method or methods of disposition thereof, such Sponsor Holder may make a written request (a “Shelf Takedown Request” and such Sponsor Holder, the
“Requesting Holder”) to the Company to effect a Public Offering, including pursuant to an Underwritten Shelf Takedown, of all or a portion of such Sponsor Holder’s Registrable Securities that may be registered under such Shelf
Registration Statement, and as soon as practicable the Company shall amend or supplement the Shelf Registration Statement as necessary for such purpose (provided that the Oak Hill Post-Closing Shareholders and the TCV Post-Closing
Shareholders may not request an underwritten offering during the first twelve (12) months following the Closing Date and any such request thereafter by the Oak Hill Post-Closing Shareholders or the TCV Post-Closing Shareholders shall constitute
the Oak Hill Post-Closing Shareholders’ or the TCV Post-Closing Shareholders’, as applicable, one (1) Demand Registration Request). 

3.2.5.2.    Promptly upon receipt of a Shelf Takedown Request (but in no event more than two (2) Business Days
thereafter (or more than twenty-four (24) hours thereafter in connection with an underwritten “block trade”)) for any Underwritten Shelf Takedown, the Company shall deliver a notice (a “Shelf Takedown Notice”) to each
other Holder with Registrable Securities covered by the applicable Registration Statement, or to all other Holders if such Registration Statement is undesignated (each, a “Potential Takedown Participant”); provided that, in
the case of an underwritten “block trade,” the Company shall only deliver the Shelf Takedown Notice to Sponsor Holders. The Shelf Takedown Notice shall offer each such Potential Takedown Participant the opportunity to include in any
Underwritten Shelf Takedown such number of Registrable Securities as each such Potential Takedown Participant may request in writing. The Company shall include in the Underwritten Shelf Takedown all such Registrable Securities with respect to which
the Company has received written requests for inclusion therein within three (3) Business Days (or within twenty-four (24) hours in connection with an underwritten “block trade”) after the date that the Shelf Takedown Notice has
been delivered. Any Potential Takedown Participant’s request to participate in an Underwritten Shelf Takedown shall be binding on the Potential Takedown Participant; provided that each such Potential Takedown Participant that elects to
participate may condition its participation on the Underwritten Shelf Takedown being completed within ten (10) Business Days of its acceptance at a price per share (after giving effect 

  
 - 15 - 

 
to any underwriters’ discounts or commissions) to such Potential Takedown Participant of not less than a percentage of the closing price for the shares on their principal trading market on
the Business Day immediately prior to such Potential Takedown Participant’s election to participate, as specified in such Potential Takedown Participant’s request to participate in such Underwritten Shelf Takedown (the
“Participation Conditions”). Notwithstanding the delivery of any Shelf Takedown Notice, but subject to the Participation Conditions (to the extent applicable), all determinations as to whether to complete any Underwritten Shelf
Takedown and as to the timing, manner, price and other terms of any Underwritten Shelf Takedown contemplated by this Section 3.2.5 shall be determined by the Requesting Holder. 

3.2.5.3.    The Company shall not be obligated to take any action to effect any Underwritten Shelf Takedown if a Demand
Registration or Piggyback Registration was declared effective or an Underwritten Shelf Takedown was consummated within the preceding ninety (90) days (unless otherwise consented to by the Company). 

3.2.6.    Priority of Securities Sold Pursuant to Shelf Takedowns. If the managing underwriter or underwriters of a
proposed Underwritten Shelf Takedown, or the Requesting Holder of a proposed “block trade” conducted as an Underwritten Shelf Takedown, in each case pursuant to Section 3.2.5 advise the Company in writing that, in
its or their opinion, the number of securities requested to be included in the proposed Underwritten Shelf Takedown exceeds the number that can be sold in such Underwritten Shelf Takedown without being likely to have an adverse effect on the price,
timing or distribution of the securities offered or the market for the securities offered, the number of Registrable Securities to be included in such offering shall be (x) first, allocated to each Sponsor Holder that has requested to
participate in such Underwritten Shelf Takedown an amount equal to the lesser of (i) the number of such Registrable Securities requested to be registered or sold by such Holder, and (ii) a number of such shares equal to such Holder’s
Pro Rata Portion, and (y) second, and only if all the securities referred to in clause (x) have been included, the number of other securities that, in the opinion of such managing underwriter or underwriters (or Requesting Holder, as the
case may be) can be sold without having such adverse effect. 
 3.3.    Piggyback Registration. 

3.3.1.    Participation. At any time after the Closing Date, if the Company at any time proposes to file a
Registration Statement under the Securities Act or to conduct a Public Offering with respect to any offering of its equity securities for its own account or for the account of any other Persons (other than (i) a Registration under Sections
3.1 or 3.2, (ii) a Registration on Form S-4 or Form S-8 or any successor form to such forms or (iii) a Registration of securities solely relating to an
offering and sale to employees or directors of the Company or its subsidiaries pursuant to any employee stock plan or other employee benefit plan arrangement), then, as soon as practicable (but in no event less than five (5) Business Days prior
to the proposed date of filing of such Registration Statement or, in the case of a Public Offering under a Shelf Registration Statement, the anticipated pricing or trade date), the Company shall give written notice (a “Piggyback
Notice”) of such proposed filing or Public Offering to all Sponsor Holders, and such Piggyback Notice shall offer such Sponsor Holders the opportunity to register under such Registration Statement, or to sell in such Public Offering, such
number of Registrable Securities as each such Sponsor Holder may request in writing (a “Piggyback Registration”). Subject to Section 3.3.2, the Company shall include in such Registration Statement or in
such Public Offering 

  
 - 16 - 

 
as applicable, all such Registrable Securities that are requested to be included therein within three (3) Business Days after the receipt by such Holder of any such notice; provided,
however, that if at any time after giving written notice of its intention to register or sell any securities and prior to the effective date of the Registration Statement filed in connection with such Registration, or the pricing or trade
date of a Public Offering under a Shelf Registration Statement, the Company determines for any reason not to register or sell or to delay the Registration or sale of such securities, the Company shall give written notice of such determination to
each Holder included therein and, thereupon, (x) in the case of a determination not to register or sell, shall be relieved of its obligation to register or sell any Registrable Securities in connection with such Registration or Public Offering
(but not from its obligation to pay the Registration Expenses in connection therewith), without prejudice, however, to the rights of any Holders entitled to request that such Registration or sale be effected as a Demand Registration under
Section 3.1 or an Underwritten Shelf Takedown under Section 3.2, as the case may be, and (y) in the case of a determination to delay Registration or sale, in the absence of a request for a
Demand Registration or an Underwritten Shelf Takedown, as the case may be, shall be permitted to delay registering or selling any Registrable Securities, for the same period as the delay in registering or selling such other securities. Any Holder
shall have the right to withdraw all or part of its request for inclusion of its Registrable Securities in a Piggyback Registration by giving written notice to the Company of its request to withdraw, prior to the applicable Registration Statement
becoming effective or, in connection with an Underwritten Shelf Takedown, the execution of the related underwriting agreement. 

3.3.2.    Priority of Piggyback Registration. If the managing underwriter or underwriters of any proposed offering
of Registrable Securities included in a Piggyback Registration informs the Company and the participating Holders in writing that, in its or their opinion, the number of securities that such Holders and any other Persons intend to include in such
offering exceeds the number that can be sold in such offering without being likely to have a significant adverse effect on the price, timing or distribution of the securities offered or the market for the securities offered, then the securities to
be included in such Registration shall be (i) first, one hundred percent (100%) of the securities that the Company proposes to sell; (ii) second, and only if all the securities referred to in clause (i) have been included, the number
of Registrable Securities that, in the opinion of such managing underwriter or underwriters, can be sold without having such adverse effect, with such number to be allocated among the Holders that have requested to participate in such Registration
based on an amount equal to the lesser of (x) the number of such Registrable Securities requested to be sold by such Holder, and (y) a number of such shares equal to such Holder’s Pro Rata Portion; (iii) third, and only if all of
the Registrable Securities referred to in clause (ii) have been included in such Registration, any other securities eligible for inclusion in such Registration. 

3.3.3.    No Effect on Other Registrations. No Registration of Registrable Securities effected pursuant to a
request under this Section 3.3 shall be deemed to have been effected pursuant to Sections 3.1 and 3.2 or shall relieve the Company of its obligations under Sections 3.1 and 3.2. 

3.4.    Lock-Up Agreements. 

3.4.1.    Each Investor agrees that such Investor shall not Transfer any Shares or any securities convertible into or
exercisable or exchangeable (directly or indirectly) for the Shares 

  
 - 17 - 

 
(including new Shares issued in connection with the transactions contemplated by the Business Combination Agreement) (such restriction, the
“Lock-Up”) during the period commencing on the Closing Date and ending on the earlier of (a) the date that is one hundred eighty (180) days following the Closing Date and
(b) the first date on which the Lock-Up Release Condition is satisfied (such period, the “Lock-Up Period”). The
Lock-Up is expressly agreed to preclude each Investor during the Lock-Up Period from engaging in any hedging or other transaction which is designed to or which
reasonably could be expected to lead to or result in a sale or disposition of such Investor’s Shares even if such Shares would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions during the Lock-Up Period shall include any short sale or any purchase, sale or grant of any right (including any put or call option) with respect to any of the Investor’s Shares or with respect to any security that
includes, relates to, or derives any significant part of its value from such Shares. The foregoing notwithstanding, (a) each executive officer and director of the Company shall be permitted to establish a plan to acquire and sell Shares
pursuant to Rule 10b5-1 under the Exchange Act, provided that such plan does not provide for the Transfer of Shares during the Lock-up Period and (b) any release or
waiver from the restrictions contained in this Section 3.4.1 prior to the expiration of the Lock-Up Period shall require the prior written consent of the Dragoneer Sponsor, and to the
extent any Sponsor Investor or Dragoneer Post-Closing Shareholder is granted a release or waiver from the restrictions contained in this Section 3.4.1 prior to the expiration of the
Lock-Up Period, then all Sponsor Investors and Dragoneer Post-Closing Shareholders shall be automatically granted a release or waiver from the restrictions contained in this
Section 3.4.1 to the same extent, on substantially the same terms as and on a pro rata basis with, the Sponsor Investor to which such release or waiver is granted. The foregoing restrictions shall not apply to Transfers of non-controlling limited partnership or other non-controlling ownership interests in any Sponsor Investor to any Affiliate of such Sponsor Investor or non-controlling limited partnership or other non-controlling ownership interests in the Dragoneer Sponsor to any Person listed on Schedule C hereto or Transfers made:
(i) pursuant to a bona fide gift or charitable contribution; (ii) by will or intestate succession upon the death of an Individual Investor; (iii) to any Permitted Transferee; (iv) pursuant to a court order or settlement agreement
related to the distribution of assets in connection with the dissolution of marriage or civil union; (v) pro rata to the partners, members or shareholders of a Sponsor Investor upon its liquidation or dissolution; or (vi) in the event of
the Company’s completion of a liquidation, merger, share exchange or other similar transaction which results in all of its shareholders having the right to exchange their Common Stock for cash, securities or other property; provided
that, in the case of (i), (iii) or (v), the recipient of such Transfer must enter into a written agreement agreeing to be bound by the terms of this Agreement, including the transfer restrictions set forth in this
Section 3.4.1. 
 3.4.2.    Each Sponsor Investor also agrees, and the Company agrees and
shall cause each director and officer of the Company to agree, that, in connection with each Registration or sale of Registrable Securities pursuant to Section 3.1, 3.2 or 3.3 conducted as an Underwritten
Public Offering, if requested, to become bound by and to execute and deliver a customary lock-up agreement with the underwriter(s) of such Underwritten Public Offering restricting such applicable person or
entity’s right to (a) Transfer, directly or indirectly, any equity securities of the Company held by such person or entity or (b) enter into any swap or other arrangement that transfers to another any of the economic consequences of
ownership of such securities during the period commencing on the date of the final Prospectus relating to the Underwritten Public Offering and ending on the date specified by the underwriters (such period not to exceed ninety (90) days). The

  
 - 18 - 

 
terms of such lock-up agreements shall be negotiated among the applicable Sponsor Investors requested to enter into
lock-up agreements in accordance with the immediately preceding sentence, the Company and the underwriters and shall include customary exclusions from the restrictions on Transfer set forth therein, including
that such restrictions on the applicable Sponsor Investors shall be conditioned upon all officers and directors of the Company, as well as all Sponsor Investors, being subject to the same restrictions; provided that, to the extent any Sponsor
Investor is granted a release or waiver from the restrictions contained in this Section 3.4.2 and in such Sponsor Investor’s lock-up agreement prior to the expiration of the
period set forth in such Sponsor Investor’s lock-up agreement, then all Sponsor Investors shall be automatically granted a release or waiver from the restrictions contained in this
Section 3.4.2 and the applicable lock-up agreements to which they are party to the same extent, on substantially the same terms as and on a pro rata basis with, the Sponsor Investor
to which such release or waiver is granted. The provisions of this Section 3.4.2 shall not apply to any Sponsor Investor that holds less than one percent (1%) of then total issued and outstanding Common Stock.  

3.5.    Registration Procedures. 

3.5.1.    Requirements. In connection with the Company’s obligations under Sections 3.1 through
3.4, the Company shall use its reasonable best efforts to effect such Registration and to permit the sale of such Registrable Securities in accordance with the intended method or methods of distribution thereof as expeditiously as reasonably
practicable, and in connection therewith the Company shall: 
 3.5.1.1.    As promptly as practicable prepare the
required Registration Statement, including all exhibits and financial statements required under the Securities Act to be filed therewith, and Prospectus, and, before filing a Registration Statement or Prospectus or any amendments or supplements
thereto, (x) furnish to the underwriters, if any, and to the Holders of the Registrable Securities covered by such Registration Statement, copies of all documents prepared to be filed, which documents shall be subject to the review of such
underwriters and such Holders and their respective counsel, (y) make such changes in such documents concerning the Holders prior to the filing thereof as such Holders, or their counsel, may reasonably request and (z) except in the case of
a Registration under Section 3.3 not file any Registration Statement or Prospectus or amendments or supplements thereto to which the Holders, in such capacity, or the underwriters, if any, shall reasonably object; 

3.5.1.2.    prepare and file with the SEC such amendments and post-effective amendments to such Registration Statement and
supplements to the Prospectus as may be (x) reasonably requested by any Holder with Registrable Securities covered by such Registration Statement, (y) reasonably requested by any participating Holder (to the extent such request relates to
information relating to such Holder), or (z) necessary to keep such Registration Statement effective for the period of time required by this Agreement, and comply with provisions of the applicable securities laws with respect to the sale or
other disposition of all securities covered by such Registration Statement during such period in accordance with the intended method or methods of disposition by the sellers thereof set forth in such Registration Statement; 

  
 - 19 - 

 3.5.1.3.    notify the participating Holders and the managing
underwriter or underwriters, if any, and (if requested) confirm such notice in writing and provide copies of the relevant documents, as soon as reasonably practicable after notice thereof is received by the Company (i) when the applicable
Registration Statement or any amendment thereto has been filed or becomes effective, and when the applicable Prospectus or any amendment or supplement thereto has been filed; (ii) of any written comments by the SEC, or any request by the SEC or
other federal or state governmental authority for amendments or supplements to such Registration Statement or such Prospectus, or for additional information (whether before or after the effective date of the Registration Statement) or any other
correspondence with the SEC relating to, or which may affect, the Registration; (iii) of the issuance by the SEC of any stop order suspending the effectiveness of such Registration Statement or any order by the SEC or any other regulatory
authority preventing or suspending the use of any preliminary or final Prospectus or the initiation or threatening of any proceedings for such purposes; (iv) if, at any time, the representations and warranties of the Company in any applicable
underwriting agreement cease to be true and correct in all material respects; and (v) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities for offering or sale in
any jurisdiction or the initiation or threatening of any proceeding for such purpose; 
 3.5.1.4.    promptly notify
each selling Holder and the managing underwriter or underwriters, if any, when the Company becomes aware of the happening of any event as a result of which the applicable Registration Statement or the Prospectus included in such Registration
Statement (as then in effect) contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein (in the case of such Prospectus or any preliminary Prospectus, in light of the circumstances
under which they were made) not misleading, when any Issuer Free Writing Prospectus includes information that may conflict with the information contained in the Registration Statement, or, if for any other reason, it shall be necessary during such
time period to amend or supplement such Registration Statement or Prospectus in order to comply with the Securities Act and, as promptly as reasonably practicable thereafter, prepare and file with the SEC, and furnish without charge to the selling
Holders and the managing underwriter or underwriters, if any, an amendment or supplement to such Registration Statement or Prospectus, which shall correct such misstatement or omission or effect such compliance; 

3.5.1.5.    to the extent the Company is eligible under the relevant provisions of Rule 430B under the Securities
Act, if the Company files any Shelf Registration Statement, the Company shall include in such Shelf Registration Statement such disclosures as may be required by Rule 430B under the Securities Act (referring to the unnamed selling security holders
in a generic manner by identifying the initial offering of the securities to the Holders) in order to ensure that the Holders may be added to such Shelf Registration Statement at a later time through the filing of a Prospectus supplement rather than
a post-effective amendment; 
 3.5.1.6.    use its reasonable best efforts to prevent, or obtain the withdrawal of, any
stop order or other order or notice preventing or suspending the use of any preliminary or final Prospectus; 

3.5.1.7.    promptly incorporate in a Prospectus supplement, Issuer Free Writing Prospectus or post-effective amendment
such information as the managing underwriter or underwriters and the participating Holders agree should be included therein relating to the plan of distribution with respect to such Registrable Securities; and make all required filings of such
Prospectus 

  
 - 20 - 

 
supplement, Issuer Free Writing Prospectus or post-effective amendment as soon as reasonably practicable after being notified of the matters to be incorporated in such Prospectus supplement,
Issuer Free Writing Prospectus or post-effective amendment; 
 3.5.1.8.    furnish to each selling Holder and each
underwriter, if any, without charge, as many conformed copies as such Holder or underwriter may reasonably request of the applicable Registration Statement and any amendment or post-effective amendment or supplement thereto, including financial
statements and schedules, all documents incorporated therein by reference and all exhibits (including those incorporated by reference); 

3.5.1.9.    deliver to each selling Holder and each underwriter, if any, without charge, as many copies of the applicable
Prospectus (including each preliminary Prospectus) and any amendment or supplement thereto and such other documents as such Holder or underwriter may reasonably request in order to facilitate the disposition of the Registrable Securities by such
Holder or underwriter (it being understood that the Company shall consent to the use of such Prospectus or any amendment or supplement thereto by each of the selling Holders and the underwriters, if any, in connection with the offering and sale of
the Registrable Securities covered by such Prospectus or any amendment or supplement thereto); 
 3.5.1.10.    on or
prior to the date on which the applicable Registration Statement becomes effective, use its reasonable best efforts to register or qualify, and cooperate with the selling Holders, the managing underwriter or underwriters, if any, and their
respective counsel, in connection with the Registration or qualification of such Registrable Securities for offer and sale under the securities or “Blue Sky” laws of each state and other jurisdiction as any such selling Holder or managing
underwriter or underwriters, if any, or their respective counsel reasonably request in writing and do any and all other acts or things reasonably necessary or advisable to keep such Registration or qualification in effect for such period as required
by Section 3.1 or Section 3.2, as applicable, provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified or to
take any action which would subject it to taxation or general service of process in any such jurisdiction where it is not then so subject; 

3.5.1.11.    cooperate with the selling Holders and the managing underwriter or underwriters, if any, to facilitate the
timely preparation and delivery of certificates representing Registrable Securities to be sold and not bearing any restrictive legends and enable such Registrable Securities to be in such denominations and registered in such names as the managing
underwriters may request prior to any sale of Registrable Securities to the underwriters; 
 3.5.1.12.    use its
reasonable best efforts to cause the Registrable Securities covered by the applicable Registration Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the seller or sellers
thereof or the underwriter or underwriters, if any, to consummate the disposition of such Registrable Securities; 

3.5.1.13.    make such representations and warranties to the Holders being registered, and the underwriters or agents, if
any, in form, substance and scope as are customarily made by issuers in public offerings similar to the offering then being undertaken; 

  
 - 21 - 

 3.5.1.14.    enter into such customary agreements (including
underwriting and indemnification agreements) and take all such other actions as the participating Holders or the managing underwriter or underwriters, if any, reasonably request in order to expedite or facilitate the Registration and disposition of
such Registrable Securities; 
 3.5.1.15.    obtain for delivery to the Holders being registered and to the underwriter
or underwriters, if any, an opinion or opinions from counsel for the Company dated the most recent effective date of the Registration Statement or, in the event of an Underwritten Public Offering, the date of the closing under the underwriting
agreement, in customary form, scope and substance, which opinions shall be reasonably satisfactory to such Holders or underwriters, as the case may be, and their respective counsel; 

3.5.1.16.    in the case of an Underwritten Public Offering, obtain for delivery to the Company and the managing
underwriter or underwriters, with copies to the Holders included in such Registration or sale, a comfort letter from the Company’s independent certified public accountants or independent auditors (and, if necessary, any other independent
certified public accountants or independent auditors of any subsidiary of the Company or any business acquired by the Company for which financial statements and financial data are, or are required to be, included in the Registration Statement) in
customary form and covering such matters of the type customarily covered by comfort letters as the managing underwriter or underwriters reasonably request, dated the date of execution of the underwriting agreement and brought down to the closing
under the underwriting agreement; 
 3.5.1.17.    cooperate with each seller of Registrable Securities and each
underwriter, if any, participating in the disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made with FINRA; 

3.5.1.18.    use its reasonable best efforts to comply with all applicable securities laws and, if a Registration
Statement was filed, make available to its security holders, as soon as reasonably practicable, an earnings statement satisfying the provisions of Section 11(a) of the Securities Act and the rules and regulations promulgated thereunder; 

3.5.1.19.    provide and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by
the applicable Registration Statement; 
 3.5.1.20.    use its reasonable best efforts to cause all Registrable
Securities covered by the applicable Registration Statement to be listed on each securities exchange on which any of the Company’s equity securities are then listed or quoted and on each inter-dealer quotation system on which any of the
Company’s equity securities are then quoted; 
 3.5.1.21.    make available upon reasonable notice at reasonable
times and for reasonable periods for inspection by a representative appointed by the Holders holding a majority of Registrable Securities being sold, by any underwriter participating in any disposition to be effected pursuant to such Registration
Statement and by any attorney, accountant or other agent retained by such Holders or any such underwriter, all pertinent financial and other records and pertinent corporate documents and properties of the Company, and cause all of the Company’s
officers, directors and employees and the independent public accountants who have certified its financial 

  
 - 22 - 

 
statements to make themselves available to discuss the business of the Company and to supply all information reasonably requested by any such Person in connection with such Registration
Statement; 
 3.5.1.22.    in the case of an Underwritten Public Offering, cause the senior executive officers of the
Company to participate in the customary “road show” presentations that may be reasonably requested by the managing underwriter or underwriters in any such offering and otherwise to facilitate, cooperate with, and participate in each
proposed offering contemplated herein and customary selling efforts related thereto; 
 3.5.1.23.    take no direct or
indirect action prohibited by Regulation M under the Exchange Act; 
 3.5.1.24.    take all reasonable action to ensure
that any Issuer Free Writing Prospectus utilized in connection with any Registration complies in all material respects with the Securities Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance
with the Securities Act to the extent required thereby and, when taken together with the related Prospectus, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading; 
 3.5.1.25.    cooperate with the Holders of
Registrable Securities subject to the Registration Statement and with the managing underwriter or agent, if any, to facilitate any Charitable Gifting Event and to prepare and file with the SEC such amendments and supplements to such Registration
Statement and the Prospectus used in connection therewith as may be necessary to permit any such recipient Charitable Organization to sell in the Public Offering if it so elects; and 

3.5.1.26.    take all such other commercially reasonable actions as are necessary or advisable in order to expedite or
facilitate the disposition of such Registrable Securities in accordance with the terms of this Agreement. 

3.5.2.    Company Information Requests. The Company may require each seller of Registrable Securities as to which
any Registration or sale is being effected to furnish to the Company customary information regarding such holder and the ownership and distribution of its Registrable Securities as the Company may from time to time reasonably request in writing and
the Company may exclude from such Registration or sale the Registrable Securities of any such Holder who unreasonably fails to furnish such information within a reasonable time after receiving such request. Each Holder agrees to furnish such
information to the Company and to cooperate with the Company as reasonably necessary to enable the Company to comply with the provisions of this Agreement. 

3.5.3.    Discontinuing Registration. Each Holder agrees that, upon receipt of any notice from the Company of the
happening of any event of the kind described in Section 3.5.1.4, such Holder will discontinue disposition of Registrable Securities pursuant to such Registration Statement until such Holder’s receipt of the copies of
the supplemented or amended Prospectus contemplated by Section 3.5.1.4, or until such Holder is advised in writing by the Company that the use of the Prospectus may be resumed, and has received copies of any additional or

  
 - 23 - 

 
supplemental filings that are incorporated by reference in the Prospectus, or any amendments or supplements thereto, and if so directed by the Company, such Holder shall deliver to the Company
(at the Company’s expense) all copies, other than permanent file copies then in such Holder’s possession, of the Prospectus covering such Registrable Securities current at the time of receipt of such notice. In the event the Company shall
give any such notice, the period during which the applicable Registration Statement is required to be maintained effective shall be extended by the number of days during the period from and including the date of the giving of such notice to and
including the date when each seller of Registrable Securities covered by such Registration Statement either receives the copies of the supplemented or amended Prospectus contemplated by Section 3.5.1.4 or is advised in
writing by the Company that the use of the Prospectus may be resumed. 
 3.6.    Underwritten Offerings. 

3.6.1.    Shelf and Demand Registrations. If requested by the underwriters for any Underwritten Public Offering,
pursuant to a Registration or sale under Sections 3.1 or 3.2, the Company shall enter into an underwriting agreement with such underwriters, such agreement to be reasonably satisfactory in substance and form to each
of the Company, the Sponsor Holders holding a majority of Registrable Securities being sold and the underwriters, and to contain such representations and warranties by the Company and such other terms as are generally prevailing in agreements of
that type, including indemnities no less favorable to the recipient thereof than those provided in Section 3.9 of this Agreement. The Sponsor Holders of the Registrable Securities proposed to be distributed by such
underwriters shall cooperate with the Company in the negotiation of the underwriting agreement and shall give consideration to the reasonable suggestions of the Company regarding the form thereof, and such Sponsor Holders shall complete and execute
all questionnaires, powers of attorney and other documents reasonably requested by the underwriters and required under the terms of such underwriting arrangements. Any such Sponsor Holder shall not be required to make any representations or
warranties to or agreements with the Company or the underwriters other than representations, warranties or agreements regarding such Sponsor Holder, such Sponsor Holder’s title to the Registrable Securities, such Sponsor Holder’s intended
method of distribution and any other representations to be made by the Sponsor Holder as are generally prevailing in agreements of that type, and the aggregate amount of the liability of such Sponsor Holder under such agreement shall not exceed such
Sponsor Holder’s proceeds from the sale of its Registrable Securities in the offering, net of underwriting discounts and commissions but before expenses. 

3.6.2.    Piggyback Registrations. If the Company proposes to register or sell any of its securities under the
Securities Act as contemplated by Section 3.3 and such securities are to be distributed through one or more underwriters, the Company shall, if requested by any Sponsor Holder pursuant to
Section 3.3 and, subject to the provisions of Section 3.3.2, use its reasonable best efforts to arrange for such underwriters to include on the same terms and conditions that apply to the other
sellers in such Registration or sale all the Registrable Securities to be offered and sold by such Holder among the securities of the Company to be distributed by such underwriters in such Registration or sale. The Holders of Registrable Securities
to be distributed by such underwriters shall be parties to a customary underwriting agreement between the Company and such underwriters and shall complete and execute all questionnaires, powers of attorney and other documents reasonably requested by
the underwriters and required under the terms of such 

  
 - 24 - 

 
underwriting arrangements. Any such Holder shall not be required to make any representations or warranties to or agreements with the Company or the underwriters other than representations,
warranties or agreements regarding such Holder, such Holder’s title to the Registrable Securities, such Holder’s intended method of distribution and any other representations to be made by the Holder as are generally prevailing in
agreements of that type, and the aggregate amount of the liability of such Holder shall not exceed such Holder’s proceeds from the sale of its Registrable Securities in the offering, net of underwriting discounts and commissions but before
expenses. 
 3.6.3.    Selection of Underwriters; Selection of Counsel. In the case of an Underwritten Public
Offering under Sections 3.1 or 3.2, the managing underwriter or underwriters to administer the offering shall be determined by the Sponsor Holders holding a majority of Registrable Securities being sold in such offering;
provided that such underwriter or underwriters shall be reasonably acceptable to the Company. In the case of an Underwritten Public Offering under Section 3.3, the managing underwriter or underwriters to administer
the offering shall be determined by the Company; provided that such underwriter or underwriters shall be reasonably acceptable to the Sponsor Holders holding a majority of Registrable Securities being sold in such offering. In the case of an
Underwritten Public Offering under Sections 3.1, 3.2 or 3.3, each participating Sponsor Holder shall be entitled to select its counsel, including, without limitation, any additional local counsel necessary to deliver any
required legal opinions. 
 3.6.4.    Non-Underwritten Offerings.
Notwithstanding anything herein to the contrary and subject to applicable law, regulation and NYSE rules, any Non-Underwritten Offering shall be conducted in accordance with the Company’s insider trading
policy to the extent that such selling stockholder is then subject to such policy. 
 3.7.    No Inconsistent
Agreements; Additional Rights. Neither the Company nor any of its subsidiaries shall hereafter enter into, and neither the Company nor any of its subsidiaries is currently a party to, any agreement with respect to its securities that is
inconsistent with the rights granted to the Holders by this Agreement. Without the approval of the Sponsor Holders holding a majority of the Registrable Securities then outstanding (voting together as a single class on an as-converted basis), neither the Company nor any of its subsidiaries shall enter into any agreement granting registration or similar rights to any Person, and the Company hereby represents and warrants that, as of
the date hereof, no registration or similar rights have been granted to any other Person other than pursuant to this Agreement. Notwithstanding the foregoing, the Company has entered into Subscription Agreements providing for the PIPE Financing and
entry into such agreements shall not constitute a breach of the representations and warranties and covenants set forth in this Section 3.7. 

3.8.    Registration Expenses. All expenses incident to the Company’s performance of or compliance with this
Agreement shall be paid by the Company, including (i) all registration and filing fees, and any other fees and expenses associated with filings required to be made with the SEC or FINRA, (ii) all fees and expenses in connection with compliance
with any securities or “Blue Sky” laws (including reasonable fees and disbursements of counsel for the underwriters in connection with blue sky qualifications of the Registrable Securities), (iii) all printing, duplicating, word
processing, messenger, telephone, facsimile and delivery expenses (including expenses of printing certificates for the Registrable Securities in a form eligible for deposit with The Depository Trust Company and of printing Prospectuses), (iv) all
fees and disbursements of 

  
 - 25 - 

 
counsel for the Company and of all independent certified public accountants or independent auditors of the Company and any subsidiaries of the Company (including the expenses of any special audit
and comfort letters required by or incident to such performance), (v) Securities Act liability insurance or similar insurance if the Company so desires or the underwriters so require in accordance with then-customary underwriting practice,
(vi) all fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange or quotation of the Registrable Securities on any inter-dealer quotation system, (viii) all reasonable
fees and disbursements of legal counsel for each selling Sponsor Holder, (ix) any reasonable fees and disbursements of underwriters customarily paid by issuers or sellers of securities, (x) all fees and expenses incurred in
connection with the distribution or Transfer of Registrable Securities to or by a Sponsor Holder or its Permitted Transferees in connection with a Public Offering, (xi) all fees and expenses of any special experts or other Persons
retained by the Company in connection with any Registration or sale, (xii) all of the Company’s internal expenses (including all salaries and expenses of its officers and employees performing legal or accounting duties) and
(xiii) all expenses related to the “road show” for any Underwritten Public Offering, including the reasonable out-of-pocket expenses of the Sponsor Holders and underwriters, if so requested. All such expenses are referred to
herein as “Registration Expenses”. The Company shall not be required to pay any fees and disbursements to underwriters not customarily paid by the issuers of securities in an offering similar to the applicable offering, including
underwriting discounts and commissions and transfer taxes, if any, attributable to the sale of Registrable Securities. 

3.9.    Indemnification. 

3.9.1.    Indemnification by the Company. The Company shall indemnify and hold harmless, to the fullest extent
permitted by law, each Holder, each shareholder, member, limited or general partner of such Holder, each shareholder, member, limited or general partner of each such shareholder, member, limited or general partner, each of their respective
Affiliates, officers, directors, shareholders, employees, advisors, and agents and each Person who controls (within the meaning of the Securities Act or the Exchange Act) such Persons and each of their respective Representatives from and against any
and all losses, penalties, judgments, suits, costs, claims, damages, liabilities and expenses, joint or several (including reasonable costs of investigation and legal expenses and any indemnity and contribution payments made to underwriters ) (each,
a “Loss” and collectively “Losses”) arising out of or based upon (i) any untrue or alleged untrue statement of a material fact contained in any Registration Statement under which such Registrable Securities are
registered or sold under the Securities Act (including any final, preliminary or summary Prospectus contained therein or any amendment thereof or supplement thereto or any documents incorporated by reference therein) or any other disclosure document
produced by or on behalf of the Company or any of its subsidiaries including any report and other document filed under the Exchange Act, (ii) any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein (in the case of a Prospectus or preliminary Prospectus, in light of the circumstances under which they were made) not misleading or (iii) any violation or alleged violation by the Company or any of its
subsidiaries of any federal, state, foreign or common law rule or regulation applicable to the Company or any of its subsidiaries and relating to action or inaction in connection with any such Registration, disclosure document or other document or
report; provided, that no selling Holder shall be entitled to indemnification pursuant to this Section 3.9.1 in respect of any untrue statement or omission contained in any information relating to such selling Holder
furnished in writing by such selling 

  
 - 26 - 

 
Holder to the Company specifically for inclusion in a Registration Statement and used by the Company in conformity therewith (such information “Selling Stockholder Information”).
This indemnity shall be in addition to any liability the Company may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Holder or any indemnified party and shall survive
the Transfer of such securities by such Holder and regardless of any indemnity agreed to in the underwriting agreement that is less favorable to the Holders. The Company shall also indemnify underwriters, selling brokers, dealer managers and similar
securities industry professionals participating in the distribution, their officers and directors and each Person who controls such Persons (within the meaning of the Securities Act and the Exchange Act) to the same extent as provided above (with
appropriate modification) with respect to the indemnification of the indemnified parties. 

3.9.2.    Indemnification by the Selling Holders. Each selling Holder agrees (severally and not jointly) to
indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors and officers and each Person who controls the Company (within the meaning of the Securities Act or the Exchange Act) from and against any Losses
resulting from (i) any untrue statement of a material fact in any Registration Statement under which such Registrable Securities were registered or sold under the Securities Act (including any final, preliminary or summary Prospectus contained
therein or any amendment thereof or supplement thereto or any documents incorporated by reference therein) or (ii) any omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the
case of a Prospectus or preliminary Prospectus, in light of the circumstances under which they were made) not misleading, in each case to the extent, but only to the extent, that such untrue statement or omission is contained in such selling
Holder’s Selling Stockholder Information. In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the proceeds from the sale of its Registrable Securities in the offering giving rise to
such indemnification obligation, net of underwriting discounts and commissions but before expenses, less any amounts paid by such Holder pursuant to Section 3.9.4 and any amounts paid by such Holder as a result of
liabilities incurred under the underwriting agreement, if any, related to such sale. 
 3.9.3.    Conduct of
Indemnification Proceedings. Any Person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that any delay or
failure to so notify the indemnifying party shall relieve the indemnifying party of its obligations hereunder only to the extent, if at all, that it forfeits substantive legal rights by reason of such delay or failure) and (ii) permit such
indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided, however, that any Person entitled to indemnification hereunder shall have the right to select and employ
separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses,
(b) the indemnifying party shall have failed to assume the defense of such claim within a reasonable time after receipt of notice of such claim from the Person entitled to indemnification hereunder and employ counsel reasonably satisfactory to
such Person, (c) the indemnified party has reasonably concluded (based upon advice of its counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the
indemnifying party, or (d) in the reasonable judgment of any such Person (based upon advice of its counsel) a conflict of interest may exist between such Person and the indemnifying party with respect to such claims (in which

  
 - 27 - 

 
case, if the Person notifies the indemnifying party in writing that such Person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have
the right to assume the defense of such claim on behalf of such Person). If the indemnifying party assumes the defense, the indemnifying party shall not have the right to settle such action without the consent of the indemnified party. No
indemnifying party shall consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of an unconditional release from all
liability in respect to such claim or litigation without the prior written consent of such indemnified party. If such defense is not assumed by the indemnifying party, the indemnifying party will not be subject to any liability for any settlement
made without its prior written consent, but such consent may not be unreasonably withheld. It is understood that the indemnifying party or parties shall not, except as specifically set forth in this Section 3.9.3, in
connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements or other charges of more than one separate firm admitted to practice in such jurisdiction at any one time unless
(x) the employment of more than one counsel has been authorized in writing by the indemnifying party or parties, (y) an indemnified party has reasonably concluded (based on the advice of counsel) that there may be legal defenses available
to it that are different from or in addition to those available to the other indemnified parties or (z) a conflict or potential conflict exists or may exist (based upon advice of counsel to an indemnified party) between such indemnified party
and the other indemnified parties, in each of which cases the indemnifying party shall be obligated to pay the reasonable fees and expenses of such additional counsel or counsels. 

3.9.4.    Contribution. If for any reason the indemnification provided for in
Section 3.9.1 and Section 3.9.2 is unavailable to an indemnified party or insufficient in respect of any Losses referred to therein (other than as a result of exceptions or limitations on
indemnification contained in Section 3.9.1 and Section 3.9.2), then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such Loss in such
proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party or parties on the other hand in connection with the acts, statements or omissions that resulted in such Losses, as well as
any other relevant equitable considerations. In connection with any Registration Statement filed with the SEC by the Company, the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand shall be
determined by reference to, among other things, whether any untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the
indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission, it being understood and agreed that, with respect to each selling Holder, such information
will be limited to such Holder’s Selling Stockholder Information. The parties hereto agree that it would not be just or equitable if contribution pursuant to this Section 3.9.4 were determined by pro rata
allocation or by any other method of allocation that does not take account of the equitable considerations referred to in this Section 3.9.4. No Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The amount paid or payable by an indemnified party as a result of the Losses referred to in
Sections 3.9.1 and 3.9.2 shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or
claim. Notwithstanding the provisions of this Section 3.9.4, in connection with any Registration Statement filed by the 

  
 - 28 - 

 
Company, a selling Holder shall not be required to contribute any amount in excess of the dollar amount of the proceeds from the sale of its Registrable Securities in the offering giving rise to
such indemnification obligation, net of underwriting discounts and commissions but before expenses, less any amounts paid by such Holder pursuant to Section 3.9.2 and any amounts paid by such Holder as a result of
liabilities incurred under the underwriting agreement, if any, related to such sale. If indemnification is available under this Section 3.9, the indemnifying parties shall indemnify each indemnified party to the full extent
provided in Sections 3.9.1 and 3.9.2 hereof without regard to the provisions of this Section 3.9.4. The remedies provided for in this Section 3.9 are not exclusive and shall not limit
any rights or remedies which may otherwise be available to any indemnified party at law or in equity. 

3.9.5.    Indemnification Priority. The Company hereby acknowledges and agrees that any of the Persons entitled to
indemnification pursuant to Section 3.9.1 (each, a “Company Indemnitee” and collectively, the “Company Indemnitees”) may have certain rights to indemnification, advancement of expenses
and/or insurance provided by other sources. The Company hereby acknowledges and agrees (i) that it is the indemnitor of first resort (i.e., its obligations to a Company Indemnitee are primary and any obligation of such other sources to advance
expenses or to provide indemnification for the same expenses or liabilities incurred by such Company Indemnitee are secondary) and (ii) that it shall be required to advance the full amount of expenses incurred by a Company Indemnitee and shall
be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement without regard to any rights a Company Indemnitee may have
against such other sources. The Company further agrees that no advancement or payment by such other sources on behalf of a Company Indemnitee with respect to any claim for which such Company Indemnitee has sought indemnification, advancement of
expenses or insurance from the Company shall affect the foregoing, and that such other sources shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Company
Indemnitee against the Company. 
 3.10.    Rules 144 and 144A and Regulation S. The Company shall file
the reports required to be filed by it under the Securities Act and the Exchange Act and the rules and regulations adopted by the SEC thereunder (or, if the Company is not required to file such reports, it will, upon the request of any Holder, make
publicly available such necessary information for so long as necessary to permit sales that would otherwise be permitted by this Agreement pursuant to Rule 144, Rule 144A or Regulation S under the Securities Act, as such rules may be amended from
time to time or any similar rule or regulation hereafter adopted by the SEC), and it will take such further action as any Holder may reasonably request, all to the extent required from time to time to enable such Holder to sell Registrable
Securities without Registration under the Securities Act in transactions that would otherwise be permitted by this Agreement and within the limitation of the exemptions provided by (i) Rule 144, Rule 144A or Regulation S under the
Securities Act, as such rules may be amended from time to time, or (ii) any similar rule or regulation hereafter adopted by the SEC. Upon the request of any Holder, the Company will deliver to such Holder a written statement as to whether it
has complied with such requirements and, if not, the specifics thereof. 
 3.11.    Existing Registration
Statements. Notwithstanding anything herein to the contrary and subject to applicable law and regulation, the Company may satisfy any obligation hereunder to file a Registration Statement or to have a Registration Statement become effective by a
specified 

  
 - 29 - 

 
date by designating, by notice to the Holders, a Registration Statement that previously has been filed with the SEC or become effective, as the case may be, as the relevant Registration Statement
for purposes of satisfying such obligation, and all references to any such obligation shall be construed accordingly; provided that such previously filed Registration Statement may be, and is, amended or, subject to applicable securities
laws, supplemented to add the number of Registrable Securities, and, to the extent necessary, to identify as selling stockholders those Holders demanding the filing of a Registration Statement pursuant to the terms of this Agreement. To the extent
this Agreement refers to the filing or effectiveness of other Registration Statements, by or at a specified time and the Company has, in lieu of then filing such Registration Statements or having such Registration Statements become effective,
designated a previously filed or effective Registration Statement as the relevant Registration Statement for such purposes, in accordance with the preceding sentence, such references shall be construed to refer to such designated Registration
Statement, as amended or supplemented in the manner contemplated by the immediately preceding sentence. 
 ARTICLE IV 

SHAREHOLDER RIGHTS AND RELATED PROVISIONS 

4.1.    Board of Directors. 

4.1.1.    Structure and Composition. From and after the Closing and until the Final Advent Step-Down Date, the
Company shall take all Necessary Action to (a) cause the total number of Directors not to be (without the Advent Post-Closing Shareholders’ prior written consent) more than nine, (b) cause the Directors to be divided into three
classes, constituted in accordance with Section 4.1.2, and (c) cause the Board to be composed solely of the individuals designated or nominated for election or appointment as Directors or a non-voting board observer, as applicable, pursuant to Section 4.1.3, Section 4.1.4, Section 4.1.5,
Section 4.1.6, Section 4.1.7, Section 4.1.8 or Section 4.1.9, as applicable, and otherwise constituted in accordance with the other provisions of
this Section 4.1. 
 4.1.2.    Classified Board. The Directors shall be divided into
three classes, designated Class I, Class II and Class III, respectively, among which the total number of Directors shall be apportioned as nearly equally as possible. The initial Class I Directors shall initially serve for a term
expiring at the first annual meeting of stockholders of the Company to be held following the Closing Date. The initial Class II Directors shall initially serve for a term expiring at the second annual meeting of stockholders of the Company to
be held following the Closing Date. The initial Class III Directors shall initially serve for a term expiring at the third annual meeting of stockholders of the Company to be held following the Closing Date. At each annual meeting of
stockholders of the Company, Directors elected to succeed those Directors whose terms expire at such annual meeting shall be elected for a term of office to expire at the third annual meeting of stockholders of the Company following their election.
From and after the Closing and until the First Advent Step-Down Date, one individual designated by Advent pursuant to clause (ii) of Section 4.1.4.1 shall be nominated to serve as a Class I Director, one
individual designated by Advent pursuant to clause (ii) of Section 4.1.4.1 shall be nominated to serve as a Class II Director and one individual designated by Advent pursuant to clause (ii) of
Section 4.1.4.1 shall be nominated to serve as a Class III Director. 

  
 - 30 - 

 4.1.3.    Initial Composition. Upon the Closing, the Board
initially shall be composed of (a) nine Directors, consisting of (i) three Independent Directors designated by the Advent Post-Closing Shareholders collectively, who initially shall be (A) Teri Williams, who shall serve as a
Class I Director, (B) William Ingram, who shall serve as a Class II Director, and (C) Eileen Schloss, who shall serve as a Class III Director; (ii) three Directors designated by the Advent Post-Closing Shareholders
collectively, who initially shall be (A) Christopher Egan, who shall serve as a Class I Director, (B) Lauren Young, who shall serve as a Class II Director, and (C) Eric Wei, who shall serve as a Class III Director;
(iii) one Director designated by the Oak Hill Post-Closing Shareholders collectively, who initially shall be Steven Puccinelli, who shall serve as a Class I Director; (iv) one director designated by the TCV Post-Closing Shareholders
collectively, who initially shall be David Yuan, who shall serve as a Class II Director; and (v) Githesh Ramamurthy, who shall serve as a Class III Director; and (b) one non-voting board
observer designated by the Dragoneer Post-Closing Shareholders collectively, who initially shall be Christian Jensen. 

4.1.4.    Advent Representation. The Advent Post-Closing Shareholders collectively shall have the right to
designate for election or appointment as Directors: 
 4.1.4.1.     during the period beginning at the Closing and
ending on the First Advent Step-Down Date, (a) three individuals, each of whom would be an Independent Director if elected, selected in the sole discretion of the Advent Post-Closing Shareholders collectively and (ii) three individuals
selected in the sole discretion of the Advent Post-Closing Shareholders collectively; 
 4.1.4.2.    during the period
beginning after the First Advent Step-Down Date and ending on the Second Advent Step-Down Date, (i) two individuals, each of whom would be an Independent Director if elected, selected in the sole discretion of the Advent Post-Closing
Shareholders collectively and (ii) two individuals selected in the sole discretion of the Advent Post-Closing Shareholders collectively; and 

4.1.4.3.    during the period beginning after the Second Advent Step-Down Date and ending on the Final Advent Step-Down
Date, (i) one individual, who would be an Independent Director if elected, selected in the sole discretion of the Advent Post-Closing Shareholders collectively and (ii) one individual selected in the sole discretion of the Advent
Post-Closing Shareholders collectively. 
 4.1.5.    Oak Hill Representation. During the period beginning at the
Closing and ending on the Oak Hill Step-Down Date, the Oak Hill Post-Closing Shareholders collectively shall have the right to designate one individual, selected in the sole discretion of the Oak Hill Post-Closing Shareholders collectively, for
election or appointment as a Director. 
 4.1.6.    TCV Representation. During the period beginning at the
Closing and ending on the TCV Step-Down Date, the TCV Post-Closing Shareholders collectively shall have the right to designate one individual, selected in the sole discretion of the TCV Post-Closing Shareholders collectively, for election or
appointment as a Director. 
 4.1.7.    Dragoneer Representation. During the period beginning at the Closing and
ending on the Dragoneer Step-Down Date, the Dragoneer Post-Closing Shareholders collectively shall have the right to designate one individual, selected in the sole discretion of the Dragoneer Post-Closing Shareholders collectively, for election or
appointment as a Director or a non-voting board observer. 

  
 - 31 - 

 4.1.8.    Chief Executive Officer. During the period in which any
individual serves as the chief executive officer of the Company, such individual shall be designated for election or appointment as a Director. 

4.1.9.    Other Directors. If, at any time, the total number of Directors then authorized to serve on the Board
exceeds the total number of individuals designated for election or appointment as Directors pursuant to Section 4.1.4, Section 4.1.5, Section 4.1.6,
Section 4.1.7 or Section 4.1.8, as applicable (whether as a result of a decrease in the number of individuals that any Sponsor Investor is entitled to so designate, any Sponsor Investor’s
election not to exercise all or part of its designation rights, or otherwise), the nominating and corporate governance committee of the Board shall select a number of individuals to be nominated for election or appointment as Directors equal to the
difference of the total number of Directors then authorized to serve on the Board and the total number of individuals so designated pursuant to Section 4.1.4, Section 4.1.5,
Section 4.1.6, Section 4.1.7 or Section 4.1.8, as applicable. 

4.1.10.    Decrease in Representation. If, at any time, the number of individuals that any Sponsor Investor is
entitled to designate for election or appointment to the Board pursuant to Section 4.1.4, Section 4.1.5, Section 4.1.6 or Section 4.1.7, as
applicable, is less than the number of Directors or non-voting board observers, as applicable, designated by such Sponsor Investor then serving on the Board, then, at the request of the Board (other than in
the case of a decrease in representation due to the Advent Post-Closing Investors ceasing to have designation rights pursuant to Section 4.1.4.1 or Section 4.1.4.2, in which case the request shall
be made by a majority of the Directors who were not designated by the Advent Post-Closing Shareholders), such Sponsor Investor shall cause such a number of the Directors or non-voting board observers, as
applicable, designated by such Sponsor Investor then serving on the Board as is necessary to cause the number of Directors or non-voting board observers, as applicable, designated by such Sponsor Investor then
serving on the Board to be equal to the number of individuals that such Sponsor Investor is entitled to designate for election or appointment to the Board pursuant to Section 4.1.4, Section 4.1.5,
Section 4.1.6 or Section 4.1.7, as applicable, to tender his, her or their resignation immediately. Notwithstanding the foregoing, the Board or any committee thereof may, in its sole discretion and
with the express written consent of such individual, recommend for election or appointment as a Director or non-voting board observer an individual who has tendered his or her resignation pursuant to this
Section 4.1.10. 
 4.1.11.    Removal; Vacancies. Except as provided in
Section 4.1.10, each Sponsor Investor shall have the sole and exclusive right to remove any Director or non-voting board observer designated by such Sponsor Investor pursuant to
Section 4.1.3, Section 4.1.4, Section 4.1.5, Section 4.1.6 or Section 4.1.7, as applicable, from the Board, for any or
no reason, and the Company shall take all actions necessary to cause the removal of any Director or non-voting board observer pursuant to this Section 4.1.11 at the request of the
applicable Sponsor Investor. For so long as a Sponsor Investor has designation rights pursuant to Section 4.1.4, Section 4.1.5, Section 4.1.6 or
Section 4.1.7, as applicable, such Sponsor Investor shall have the sole and exclusive right to designate another individual for election or appointment as a Director or non-voting
board observer, as applicable, to fill any vacancy on the Board resulting from the death, removal or 

  
 - 32 - 

 
resignation of a Director or non-voting board observer, as applicable, designated by such Sponsor Investor pursuant to
Section 4.1.4, Section 4.1.5, Section 4.1.6 or Section 4.1.7, as applicable. 

4.2.    Board Committees. The Board shall establish and maintain an audit committee, a compensation committee and a
nominating and corporate governance committee, and may establish and maintain such other committees as the Board deems appropriate from time to time. Subject to applicable law, regulation and NYSE rules, for so long as any Director designated by the
Advent Post-Closing Shareholders pursuant to clause (ii) of any of Section 4.1.4.1, Section 4.1.4.2 or Section 4.1.4.3 is serving on the Board, the Advent Post-Closing Shareholders collectively shall have the right, at
their option, to have at least one such Director serve on each committee of the Board. The initial members of the Company’s audit committee shall be William Ingram, Teri Williams and Steven Puccinelli. The initial members of the Company’s
compensation committee shall be Eileen Schloss, Eric Wei, David Yuan and Githesh Ramamurthy. The initial members of the Company’s nominating and corporate governance committee shall be selected by the Advent Post-Closing Shareholders
collectively in their sole discretion. 
 4.3.    Subsidiary Boards and Committees. Subject to applicable law,
regulation and NYSE rules, for so long as any Director designated by the Advent Post-Closing Shareholders pursuant to clause (ii) of any of Section 4.1.4.1, Section 4.1.4.2 or Section 4.1.4.3
is serving on the Board, the Advent Post-Closing Shareholders collectively shall have the right, at their option, to have any or all of such Directors serve on the board of directors or similar governing body of any subsidiary of the Company and on
any committee thereof. 
 4.4.    Director Expenses. The Company shall pay the reasonable out-of-pocket costs and
expenses incurred by each Director in connection with his or her attendance at meetings of the Board, meetings of any committee of the Board on which such Director serves and meetings of any board of directors or similar governing body of any
subsidiary of the Company or any committee thereof on which such Director serves. 

4.5.    Directors’ and Officers’ Insurance. The Company (a) shall
provide each Director designated by a Sponsor Investor pursuant to Section 4.1 with the same rights, privileges and benefits as the other members of the Board, including with respect to indemnification, exculpation,
insurance coverage, expense reimbursement, notice and information, and (b) to the fullest extent permitted by applicable law, regulation and NYSE rules, shall not amend, repeal or otherwise modify in a manner adverse to any such Director
any right of such Director to indemnification or exculpation under the Certificate, the Bylaws, this Agreement or any other agreement or instrument by the Company or any of its subsidiaries without the prior written consent of a majority of the
Directors designated by a Sponsor Investor pursuant to Section 4.1 who are then serving in such capacity. The Company hereby acknowledges that any director, officer or other indemnified person to whom the Company is
obligated to provide insurance coverage, indemnification or advancement of expenses in connection therewith by the Company pursuant to the Certificate or the Bylaws or any other agreement between the Company and any such person or under which such
person has third-party beneficiary rights with respect thereto (each, a “Covered Indemnitee”, and any such obligation, an “Indemnification Obligation”) may have certain rights to indemnification, advancement of
expenses or insurance provided by one or more of the Sponsor Investors or their respective Affiliates (collectively, the “Fund Indemnitors”). The Company hereby (a) agrees that the Company shall be the indemnitor of
first resort with respect to all 

  
 - 33 - 

 
Indemnification Obligations (i.e., its Indemnification Obligations to a Covered Indemnitee shall be primary and any obligation of any Fund Indemnitor to advance expenses or to provide
indemnification for the same expenses or liabilities incurred by such Covered Indemnitee shall be secondary) and (b) irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims the Company has or may have against the
Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect of any such expenses or liabilities. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of a Covered Indemnitee with
respect to any claim for which such Covered Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution or be subrogated to the extent of such advancement or payment
to all of the rights of recovery of such Covered Indemnitee against the Company. The provisions of this Section 4.5 will survive any termination of this Agreement. Any Fund Indemnitor or insurer thereof not a party to this Agreement is
an express third-party beneficiary of this Section 4.5, and is entitled to enforce this Section 4.5 according to its terms to the same extent as if such Fund Indemnitor or insurer thereof were a
party hereto. 
 4.6.    Confidentiality. Each Investor other than the Dragoneer Post-Closing Shareholders agrees
that it will keep confidential and will not disclose, divulge or use for any purpose, other than to monitor its investment in the Company and its subsidiaries and make investment decisions with respect to the securities of the Company, any
confidential information regarding the Company or any of its subsidiaries or the business or operations thereof that has been obtained from the Company or any of its subsidiaries or by virtue of the service of any person affiliated with such
Investor as a director, manager or officer of the Company or any of its subsidiaries (any such confidential information, “Confidential Information”), unless such Confidential Information (a) becomes known to the public (other
than as a result of a breach of this Section 4.6 by such Investor or any of its Affiliates), (b) is or has been independently developed or conceived by such Investor without use of Confidential Information obtained in violation of this
Section 4.6 by such Investor or any of its Affiliates or (c) is or has been made known or disclosed to such Investor by a third party (other than an Affiliate of such Investor) without a breach of any obligation of
confidentiality such third party may have; provided, however, that an Investor may disclose Confidential Information (i) to its attorneys, accountants, consultants and other professional advisors to the extent necessary to
obtain their services in connection with monitoring its investment in the Company, (ii) to any prospective purchaser of any Shares from such Investor in any Transfer permitted under this Agreement as long as such prospective purchaser
agrees prior to such disclosure to be bound by a confidentiality agreement no less favorable to the Company than the provisions of this Section 4.6, (iii) to any Affiliate, partner, member or related investment fund of such
Investor and their respective directors, managers, officers, employees and professional advisors, in each case in the ordinary course of business, (iv) as may be reasonably determined by such Investor to be necessary in connection with such
Investor’s enforcement of its rights in connection with this Agreement or its investment in the Company and its subsidiaries or (v) as may otherwise be required by law or legal, judicial or regulatory process or requested by any
regulatory or self-regulatory authority or examiner, provided that such Investor takes reasonable steps to minimize the extent of any required or requested disclosure described in this clause (v); and provided further, however,
that the disclosing Investor shall cause any Person to whom such Investor may disclose Confidential Information pursuant to clauses (i) through (iii) of the first proviso of this sentence to comply with this Section 4.6 as if such
Person was a party hereto; and provided further, however, that the acts and omissions of any Person to whom such Investor may 

  
 - 34 - 

 
disclose Confidential Information pursuant to clauses (i) through (iii) of the first proviso of this sentence will be attributable to such Investor for purposes of determining such
Investor’s compliance with this Section 4.6. Each party hereto acknowledges that the Sponsor Investors or any of their Affiliates and related investment funds may review the business plans and related proprietary
information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company and its subsidiaries, and may trade in the securities of such enterprises. Nothing in this
Section 4.6 (except as set forth in the second proviso of the preceding sentence) will preclude or in any way restrict the Sponsor Investors or their Affiliates or related investment funds from investing or participating in
any particular enterprise, or trading in the securities thereof, whether or not such enterprise has products or services that compete with those of the Company and its subsidiaries. Notwithstanding the foregoing or anything else to the contrary in
this Agreement, each party hereto (and each director, manager, officer, employee, representative or other agent of any party hereto) may disclose to any and all Persons, without limitation of any kind, the tax treatment and tax structure of, and tax
strategies relating to, the transactions in which such party participates pursuant to this Agreement. For this purpose, “tax structure” is limited to any facts relevant to the United States federal income tax treatment of such transactions
and does not include information relating to the specific identity of the parties hereto. The Dragoneer Post-Closing Shareholders hereby agree to be bound by and subject to (a) Section 5.3(a) (Confidentiality) of the Business Combination
Agreement to the same extent as such provisions apply to the parties to the Business Combination Agreement, as if such Dragoneer Post-Closing Shareholder is directly a party thereto, and (b) the Confidentiality Agreement, dated as of
October 14, 2020 (the “Confidentiality Agreement”), by and between the Company and Chariot Target, to the same extent as such provisions apply to the Company, as if such Dragoneer Post-Closing Shareholder is directly a party
thereto; provided that, notwithstanding anything to the contrary in the Confidentiality Agreement and solely for purposes of this sentence, the Confidentiality Agreement shall be deemed to expire on, and the Dragoneer Post-Closing
Shareholders shall continue to be bound by the provisions of the Confidentiality Agreement as provided in this sentence until, the date that is one year after the Closing Date. 

4.7.    Other Business Opportunities. To the fullest extent permitted by law, the doctrine of corporate opportunity
and any analogous doctrine will not apply to (a) any Sponsor Investor, (b) any director or officer of the Company who is not a full-time employee of the Company or any of its operating subsidiaries or (c) any Affiliate,
partner, advisory board member, director, officer, manager, member or shareholder of any Sponsor Investor who is not a full-time employee of the Company or any of its operating subsidiaries (any such Person listed in (a), (b) or (c), an
“External Party”). The Company renounces any interest or expectancy of the Company in, or in being offered an opportunity to participate in, business opportunities that are from time to time presented to any External Party. Each
External Party who acquires knowledge of a potential transaction, agreement, arrangement or other matter that may be an opportunity for the Company (i) will not have any duty to communicate or offer such opportunity to the Company and
(ii) will not be liable to the Company or any of its subsidiaries or to any holder of securities of or any equity interest in the Company or any of its subsidiaries because such External Party pursues or acquires for, or directs such
opportunity to, itself or another Person or does not communicate such opportunity or information to the Company. 

  
 - 35 - 

 4.8.    Other Business Activities of Sponsor Investors. The
Company acknowledges that certain of the Sponsor Investors and their respective Affiliates are in the business of investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises that
may have products or services that compete directly or indirectly with those of the Company. Subject to compliance with the express terms of this Agreement and each other agreement related to the transactions contemplated by this Agreement
(collectively, the “Transaction Agreements”), the Sponsor Investors shall not be precluded or in any way restricted from investing or participating in any particular enterprise, whether or not such enterprise has products or
services that compete with those of the Company. 
 4.9.    Amendment of the Business Combination Agreement. The
Company shall not, and shall cause Chariot Merger Sub not to, amend, restate, supplement or otherwise modify, or waive any provision of, the Business Combination Agreement without the prior written consent of the Advent Post-Closing Shareholders.

 4.10.    Termination of Prior Chariot Target Agreement. Each of the Investors that, together with Chariot
Target, is a party to that certain Amended and Restated Stockholders Agreement, dated as of June 9, 2017 (as it may be amended, restated, supplemented or otherwise modified from time to time, the “Prior Chariot Target Agreement”),
acknowledges and agrees that, in connection with the transactions contemplated by the Business Combination Agreement, the Prior Chariot Target Agreement will be terminated in its entirety and, from and after such termination, all of the provisions
thereof shall cease to have any further force or effect and no Person shall have any further rights or obligations thereunder, except that Sections 1(f) (Board of Directors—Expenses) and 16 (Indemnification) of the Prior Chariot
Target Agreement shall remain in full force and effect in accordance with their respective terms notwithstanding such termination and none of the rights or obligations of any Person thereunder shall be impaired or otherwise affected by such
termination. 
 ARTICLE V 

MISCELLANEOUS 

5.1.    Authority; Effect. Each party hereto represents and warrants to each other party hereto that the execution
and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized on behalf of such party and do not violate any agreement or other instrument applicable to such party or by which its assets are
bound. This Agreement does not, and shall not be construed to, give rise to the creation of a partnership among any of the parties hereto, or to constitute any of such parties members of a joint venture or other association. The Company and its
subsidiaries shall be jointly and severally liable for all obligations of the Company pursuant to this Agreement. 

  
 - 36 - 

 5.2.    Notices. Any notices, requests, demands and other
communications required or permitted in this Agreement shall be effective if in writing and (a) delivered personally, (b) sent by e-mail, provided that any e-mail must be followed by confirmation copy sent by the means provided in
the following clause (c) on the same day the e-mail is sent, or (c) sent by overnight courier, in each case, addressed as follows: 

If to the Company to: 
  

					
	            	  	222 Merchandise Mart Plaza, Suite 900
		  	Chicago, IL 60654-1105
		  	Attention:	  	Githesh Ramamurthy
		  		  	Kevin Kane
		  	Email:	  	gramamurthy@cccis.com
		  		  	kkane@cccis.com
	
	with a copy (which shall not constitute notice) to:
		
		  	Kirkland & Ellis LLP
		  	601 Lexington Avenue
		  	New York, NY 10022
		  	Attention:	  	Douglas A. Ryder, P.C.
		  		  	Willard S. Boothby, P.C.
		  		  	Christian O. Nagler
		  	E-mail:	  	douglas.ryder@kirkland.com
		  		  	willard.boothby@kirkland.com
		  		  	christian.nagler@kirkland.com

 If to an Investor, to his, her or its address, with a copy (which shall not constitute notice) to his, her or its legal
counsel (if any), as set forth on Schedule A or Schedule B, as applicable. 
 Notice to the holder of record of
any Registrable Securities shall be deemed to be notice to the holder of such securities for all purposes hereof. 
 Unless otherwise
specified herein, such notices or other communications shall be deemed effective (i) on the date received, if personally delivered, (ii) the earlier of (A) non-automated confirmation of receipt
or (B) as provided in the following clause (iii), if sent by e-mail, and (iii) one (1) Business Day after being sent by overnight courier. Each of the parties hereto shall be entitled to specify a
different address by giving notice as aforesaid to each of the other parties hereto. 
 5.3.    Termination and
Effect of Termination. This Agreement may be terminated only by an agreement in writing signed by the Majority Sponsor Investors; provided that the consent of any Sponsor Investor will be required for any termination of this Agreement
which has an adverse effect on the rights, limitations or obligations of such Sponsor Investor. Notwithstanding any termination of this Agreement in accordance with the foregoing sentence, the provisions of Sections 3.8, 3.9,
3.10, 4.4 and 4.5 shall survive any such termination. No termination under this Agreement shall relieve any Person of liability for breach or Registration Expenses incurred prior to termination. In the event this Agreement is
terminated, each Person entitled to indemnification rights pursuant to Section 3.9 hereof shall retain such indemnification rights with respect to any matter that (a) may be an indemnified liability thereunder and
(b) occurred prior to such termination. Notwithstanding the foregoing or anything else herein to the contrary, upon any termination of the Business Combination Agreement in accordance with its terms, this Agreement shall automatically
terminate, without notice or other action by any party hereto, and be void ab 

  
 - 37 - 

 
initio and no party hereto shall have any obligations or liability hereunder. Upon written request to the Company, any Holder may request not to receive any Demand Notice, Piggyback
Notice, Shelf Registration Notice and/or Shelf Takedown Notice and thereafter shall not receive any such notices, unless otherwise requested in writing. 

5.4.    Permitted Transferees. The rights of a Holder hereunder may be assigned (but only with all related
obligations as set forth below) in connection with a Transfer of Registrable Securities to (a) a Permitted Transferee of that Holder or (b) in the case of any Sponsor Holder, other than the rights of such Sponsor Holder set forth in
Section 4.1, to a transferee that acquires greater than five (5) percent of the outstanding shares of the Company in a transaction exempt from the registration requirements of the Securities Act (other than Rule
144); provided that, in the case of each of the foregoing clauses (a) and (b), (i) the Oak Hill Post-Closing Shareholders collectively shall only be permitted to assign their one (1) Demand Registration hereunder, and the TCV
Post-Closing Shareholders collectively shall only be permitted to assign their one (1) Demand Registration hereunder, if such Holders have not already exercised such right, and upon such assignment, only the assignee thereof shall be permitted
to exercise such one (1) Demand Registration, and (ii) each of the Oak Hill Post-Closing Shareholders and the TCV Post-Closing Shareholders shall be permitted to assign its rights under Article 3 only to a Permitted
Transferee for so long as such Permitted Transferee remains an Affiliate of such Oak Hill Post-Closing Shareholder or such TCV Post-Closing Shareholder, as applicable, and any Permitted Transferee to which such rights are assigned in accordance with
this Section 5.4 shall no longer have such rights from and after the time such Permitted Transferee ceases to be an Affiliate of such Oak Hill Post-Closing Shareholders or such TCV Post-Closing Shareholders, as applicable.
Without prejudice to any other or similar conditions imposed hereunder with respect to any such Transfer, no assignment permitted under the terms of this Section 5.4 will be effective unless the Permitted Transferee or
other assignee to which the assignment is being made, if not a Holder, has delivered to the Company a written acknowledgment and agreement in form and substance reasonably satisfactory to the Company that the Permitted Transferee or other assignee
will be bound by, and will be a party to, this Agreement. A Permitted Transferee to whom rights are transferred pursuant to this Section 5.4 may not again transfer those rights to any other Permitted Transferee or other
assignee, other than as provided in this Section 5.4. 
 5.5.    Legend Removal. If the
Dragoneer Post-Closing Shareholders hold Registrable Securities that are eligible to be sold without restriction under Rule 144 under the Securities Act or pursuant to an effective registration statement, then, at the Dragoneer Post-Closing
Shareholders’ request, the Company will use commercially reasonable efforts to cause the Company’s transfer agent to remove any restrictive legend set forth on such Registrable Securities (including, if necessary, by delivering to the
Company’s transfer agent a direction letter). In connection therewith, if an opinion of counsel (or direction letter based upon a legal opinion) is required by the Company’s transfer agent, the Dragoneer Post-Closing Shareholder will
promptly cause an opinion of its counsel to be delivered to and maintained with the Company’s transfer agent (and to the Company, if the Company is required to deliver a direction letter), together with any other authorizations, certificates
and directions reasonably required by the transfer agent that authorize and direct the transfer agent to transfer such Registrable Securities without any such legend. 

  
 - 38 - 

 5.6.    Remedies. The parties to this Agreement shall have all
remedies available at law, in equity or otherwise in the event of any breach or violation of this Agreement or any default hereunder. The parties acknowledge and agree that in the event of any breach of this Agreement, in addition to any other
remedies that may be available, each of the parties hereto shall be entitled to specific performance of the obligations of the other parties hereto and, in addition, to such other equitable remedies (including preliminary or temporary relief) as may
be appropriate in the circumstances. No delay of or omission in the exercise of any right, power or remedy accruing to any party as a result of any breach or default by any other party under this Agreement shall impair any such right, power or
remedy, nor shall it be construed as a waiver of or acquiescence in any such breach or default, or of any similar breach or default occurring later; nor shall any such delay, omission nor waiver of any single breach or default be deemed a waiver of
any other breach or default occurring before or after that waiver. 
 5.7.    Amendments. This Agreement may not
be orally amended, modified or extended, nor shall any attempted oral waiver of any of its terms be effective. This Agreement may be amended, modified or extended, and the provisions hereof may be waived, only by an agreement in writing signed by
the Company and the Advent Post-Closing Shareholders in the case of any amendment, modification, extension or waiver effected prior to the Closing or by the Company and the Majority Sponsor Investors in the case of any amendment, modification,
extension or waiver effected at or after the Closing. Each such amendment, modification, extension or waiver shall be binding upon each party hereto; provided that (a) the consent of any Sponsor Investor shall be required for any
amendment, modification, extension or waiver which has an adverse effect on the rights, limitations or obligations of such Sponsor Investor and (b) any such amendment, modification, extension or waiver that by its terms would adversely
affect a Holder or group of Holders in a disproportionate manner relative to the Holders generally shall require the written consent of the Holder (or a majority in interest based on Registrable Securities of such group of Holders) so affected.
Notwithstanding anything herein to the contrary, Schedule B hereto may be amended, supplemented or otherwise modified from time to time by the Advent Post-Closing Shareholders to reflect the name of any holder of Registrable Securities that
was a holder Equity Securities of Chariot Target prior to the Closing and that has executed and delivered a counterpart of this Agreement. In addition, each party hereto may waive any right hereunder (solely as applicable to such party) by an
instrument in writing signed by such party. 
 5.8.     Governing Law. This Agreement, the rights of the parties
hereto under or in connection herewith or in connection with any of the transactions contemplated hereby, and all actions arising in whole or in part under or in connection herewith or therewith (whether at law or in equity, whether sounding in
contract, tort, statute or otherwise), shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any choice or conflict of laws provision or rule that would cause the application of the laws of
any other jurisdiction. 
 5.9.    Consent to Jurisdiction; Venue; Service. Each party to this Agreement, by its
execution hereof, (a) hereby irrevocably submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware located in Wilmington, Delaware, or if (but only if) such court does not have subject matter
jurisdiction, the state or federal courts located in the State of Delaware for the purpose of any suit, action or other proceeding described in Section 5.8; (b) hereby waives to the extent not prohibited by applicable
law, and agrees not to assert, and 

  
 - 39 - 

 
agrees not to allow any of its subsidiaries to assert, by way of motion, as a defense or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the
jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such suit, action or proceeding brought in one of the above-named courts is improper, or that this Agreement or the subject matter
hereof may not be enforced in or by such court; and (c) hereby agrees not to commence or maintain any such action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause
the transfer or removal of any such action to any court other than one of the above-named courts whether on the grounds of inconvenient forum or otherwise. Each party to this Agreement hereby also (i) consents to service of process in any
action described in this Section 5.9 in any manner permitted by Delaware law, (ii) agrees that service of process made in accordance with clause (i) or made by overnight delivery by a nationally recognized courier service
addressed to a party’s address specified pursuant to Section 5.2 shall constitute good and valid service of process in any such action and (iii) waives and agrees not to assert (by way of motion, as a defense or otherwise) in
any such action any claim that service of process made in accordance with clause (i) or (ii) does not constitute good and valid service of process. Notwithstanding the foregoing in this Section 5.9, a party may commence any
action in a court other than the above-named courts solely for the purpose of enforcing an order or judgment issued by one of the above-named courts. 

5.10.    WAIVER OF JURY TRIAL. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH PARTY
HERETO HEREBY WAIVES AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE) ANY RIGHT TO TRIAL BY JURY WITH RESPECT TO THIS AGREEMENT OR ANY AND ALL ACTIONS OR PROCEEDINGS (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE)
DESCRIBED IN SECTION 5.9. EACH PARTY HERETO ACKNOWLEDGES THAT IT HAS BEEN INFORMED BY THE OTHER PARTIES HERETO THAT THIS SECTION 5.10 CONSTITUTES A MATERIAL INDUCEMENT UPON WHICH THEY ARE RELYING AND WILL RELY IN ENTERING INTO
THIS AGREEMENT. ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 5.10 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY. 

5.11.    Merger; Binding Effect; Assignment. This Agreement constitutes the entire agreement of the parties
hereto with respect to the subject matter hereof, supersedes all prior or contemporaneous oral or written agreements or discussions with respect to such subject matter, and shall be binding upon and inure to the benefit of the parties hereto and
their respective heirs, successors and permitted assigns. Except as otherwise expressly provided herein, no Holder or other party hereto may assign any of its rights or delegate any of its obligations under this Agreement without the prior written
consent of the other parties hereto, and any attempted assignment or delegation in violation of the foregoing shall be null and void. 

5.12.    Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an
original, but all of which taken together shall constitute one instrument. The parties hereto agree that execution of this Agreement by industry standard electronic signature software or by exchanging executed signature pages in .pdf format via e-mail shall have the same legal force and effect as the exchange of original signatures, and each party hereto hereby waives 

  
 - 40 - 

 
any right to raise in any proceeding arising under or related to this Agreement any defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance
of the executed agreement electronically. 
 5.13.    Severability. In the event that any provision hereof would,
under applicable law, be invalid or unenforceable in any respect, such provision shall be construed by modifying or limiting it so as to be valid and enforceable to the maximum extent compatible with, and possible under, applicable law. The
provisions hereof are severable, and in the event any provision hereof should be held invalid or unenforceable in any respect, it shall not invalidate, render unenforceable or otherwise affect any other provision hereof. 

5.14.    No Recourse. Notwithstanding anything that may be expressed or implied in this Agreement, the Company and
each Holder covenant, agree and acknowledge that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, manager, employee, general or
limited partner, member or equityholder of any Holder or of any Affiliate or assignee thereof, as such, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable
law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future director, officer, manager, employee, general or limited partner, member or
equityholder of any Holder or of any Affiliate or assignee thereof, as such, for any obligation of any Holder under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or
by reason of such obligations or their creation. 
 [Remainder of page intentionally left blank. Signature pages follow.] 

  
 - 41 - 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

							
	Company:	 		 	DRAGONEER GROWTH OPPORTUNITIES CORP.
				
		 		 	By:	 	 /s/ Pat Robertson

		 		 	Name:	 	Pat Robertson
		 		 	Title:	 	President and Chief Operating Officer

 [Signature Page to Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

							
		 		 	CYPRESS INVESTOR HOLDINGS, L.P.
				
		 		 	By:	 	Cypress Investment GP. LLC, its general partner
				
		 		 	By:	 	Advent International Corporation, its sole member
				
		 		 	By:	 	 /s/ James Westra

		 		 	Name:	 	James Westra
		 		 	Title:	 	Managing Partner

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

			
	 TCV IX, L.P.

		
	 By:
	 	Technology Crossover Management IX, L.P., its general partner
		
	 By:
	 	Technology Crossover Management IX, Ltd., its general partner
		
	 By:
	 	 /s/ Frederic D. Fenton

		 	 Name:  Frederic D. Fenton

		 	
Title:    
Attorney-in-Fact

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

			
	 TCV IX (A), L.P.

		
	 By:
	 	Technology Crossover Management IX, L.P., its general partner
		
	 By:
	 	Technology Crossover Management IX, Ltd., its general partner
		
	 By:
	 	 /s/ Frederic D. Fenton

		 	 Name:  Frederic D. Fenton

		 	
Title:    
Attorney-in-Fact

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

			
	 TCV IX (B), L.P.

		
	 By:
	 	Technology Crossover Management IX, L.P., its general partner
		
	 By:
	 	Technology Crossover Management IX, Ltd., its general partner
		
	 By:
	 	 /s/ Frederic D. Fenton

		 	 Name:  Frederic D. Fenton

		 	
Title:    
Attorney-in-Fact

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

			
	 TCV MEMBER FUND, L.P.

		
	 By:
	 	Technology Crossover Management IX, Ltd., its general partner
		
	 By:
	 	 /s/ Frederic D. Fenton

		 	 Name:  Frederic D. Fenton

		 	
Title:    
Attorney-in-Fact

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

			
	 OH CYPRESS AGGREGATOR, L.P.

		
	 By:
	 	OHCP GenPar IV, L.P., its general partner
		
	 By:
	 	OHCP MGP IV, Ltd., its general partner
		
	 By:
	 	 /s/ John R. Monsky

		 	 Name:  John R. Monsky

		 	 Title:    Assistant Secretary

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

			
	GPE VIII CCC CO-INVESTMENT (DELAWARE) LIMITED PARTNERSHIP
		
	 By:
	 	Advent International Corporation, its manager
		
	 By:
	 	 /s/ Andrew D. Dodge

		 	 Name:  Andrew D. Dodge

		 	 Title:    Vice President

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

			
	ADVENT INTERNATIONAL GPE VIII-C LIMITED PARTNERSHIP
		
	 By:
	 	GPE VIII GP (Delaware) Limited Partnership, its general partner
		
	 By:
	 	Advent International GPE VIII, LLC, its general partner
		
	 By:
	 	Advent International Corporation, its manager
		
	 By:
	 	 /s/ James Westra

		 	 Name:  James Westra

		 	 Title:    Managing Partner

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

			
	 HIGGINSON ENTERPRISES, LLC

		
	 By:
	 	 /s/ Githesh Ramamurthy

		 	 Name:  Githesh Ramamurthy

		 	 Title:    Manager

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement] 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of
the date first above written. 
  

			
	 By:
	 	 /s/ Githesh Ramamurthy

		 	 Name:  Githesh Ramamurthy

  
 [Signature Page to
Amended and Restated Registration and Shareholder Rights Agreement]Exhibit 10.1

    

  

  

  

  AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT

  THIS AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT (the “Agreement”), is made effective as of January 29, 2021 between AngioDynamics, Inc., a Delaware corporation (the “Company”),

    and James C. Clemmer, an individual resident of New York (“Executive”).

  WHEREAS, the Company considers it essential to the best interests of its shareholders to foster the continued employment of
    key management personnel; and

  WHEREAS, the Board recognizes that, as is the case with many publicly held corporations, the possibility of a Change in
    Control exists and that such possibility, and the uncertainty and questions which it may raise among management, may result in the departure or distraction of management personnel to the detriment of the Company and its shareholders; and

  WHEREAS, the Board has determined that appropriate steps should be taken to reinforce and encourage the continued attention
    and dedication of members of the Company’s management, including the Executive, to their assigned duties without distraction in the face of potentially disturbing circumstances arising from the possibility of a Change in Control; and

  WHEREAS, the Company and the Executive previously entered into that certain Change in Control Agreement, dated as of April 1,
    2016 (as amended, modified, or supplemented from time to time, the “Original Agreement”), and each of the Company and the Executive desire to amend and restate the
    Original Agreement in its entirety as set forth herein;

  NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Company and the Executive
    hereby agree that the Original Agreement is hereby amended and restated in its entirety as follows:

  1.  Defined Terms. The definitions of
    capitalized terms used in this Agreement are provided in the last Section hereof.

  2.  Term of Agreement. The Term of
    this Agreement shall commence on the date hereof and shall continue in effect through December 31, 2021; provided, however, that effective January 1, 2022 and each January 1 thereafter, the Term that is then in effect shall automatically be extended
    for one additional year unless the Company has given at least sixty (60) days’ written notice before the January 1 in question that the Term that is in effect at the time such notice is given will not be extended; and further provided, however, that if
    a Change in Control occurs during the Term, the Term shall expire no earlier than twenty-four (24) calendar months after the calendar month in which such Change in Control occurs. Notwithstanding the foregoing, this Agreement shall terminate if the Executive ceases to be an employee of the Company and its subsidiaries for any reason prior to a Change in Control.  However, anything in this Agreement (including the

  
    
      

      

    

    
      

    
      

      

    

  

  
  preceding sentence) to the contrary
      notwithstanding, if a Change in Control occurs and if, within three (3) months prior to the date on which such Change in Control occurs, the Executive’s employment with the Company is terminated by the Company without Cause or an event occurs
    that would, if it took place after the Change in Control, constitute Good Reason for termination of employment by the Executive, and if it is reasonably demonstrated by the Executive that such termination of employment by the Company or event
    constituting Good Reason for termination of employment by the Executive (a) was undertaken at the request of a third party who has taken steps reasonably calculated to effect the Change in Control, or (b) otherwise arose in connection with or in
    anticipation of the Change in Control, then for purposes of this Agreement such termination of employment by the Company without Cause or event constituting Good Reason shall be deemed to occur during the twenty-four (24) month period following the
    Change in Control and, if the Executive terminates the Executive’s employment for such Good Reason before the Change in Control, such termination of employment by the Executive shall likewise be deemed to occur during the twenty-four (24) month period
    following the Change in Control (it being understood that, in each case, the Review Period (as defined below) shall be deemed to commence on the date of the applicable Change in Control).

  3.  Company’s Covenants Summarized. In
    order to induce the Executive to remain in the employ of the Company and in consideration of the Executive’s covenants set forth in Section 4 hereof, the Company agrees, under the conditions described herein, to pay the Executive the Severance Payments
    and the other payments and benefits described herein. Except as provided in Section 2, Section 6.3, Section 9.1, or Section 14.2 hereof, no amounts shall be payable under this Agreement unless the Executive’s employment with the Company terminates
    following a Change in Control and during the Term. This Agreement shall not be construed as creating an express or implied contract of employment enforceable against the Company nor, except as provided in Section 4 below, enforceable against the
    Executive, and, except as otherwise agreed in writing between the Executive and the Company, the Executive shall not have any right to be retained in the employ of the Company.

  4.  The Executive’s Covenants. The
    Executive agrees to remain in the employ of the Company, subject to the terms and conditions of this Agreement, if a Potential Change in Control occurs during the Term and the Executive is then in the employ of the Company, until the earliest of (a)
    the date which is six (6) months after the date of such Potential Change in Control, (b) the date of a Change in Control, (c) the date of termination by the Executive of the Executive’s employment for Good Reason or by reason of death, Disability, or
    Retirement, or (d) the termination by the Company of the Executive’s employment for any reason; provided that Executive’s agreement to remain in the employ of the Company shall be subject to the condition that no adverse change occurs after the
    Potential Change in Control in the Executive’s title, duties, responsibilities, authority, reporting relationships, compensation, benefits, or indemnification rights.

  
    5.  Certain Compensation Other Than Severance Payments.

  

  
    
      

      

    

    Page 2 of 30 pages

    
      

    
      

      

    

  

  

  

  5.1  If the Executive’s employment shall be terminated for any reason following a Change in Control and during the Term, the
    Company shall pay the Executive’s full salary through the date of termination at the rate in effect immediately prior to the date of termination or, if higher, the rate in effect immediately prior to the first occurrence of an event or circumstance
    constituting Good Reason, together with all compensation and benefits payable to the Executive through the date of termination under the terms of the Company’s compensation and benefit plans, programs, and arrangements as in effect immediately prior to
    the date of termination or, if more favorable to the Executive, as in effect immediately prior to the first occurrence of an event or circumstance constituting Good Reason.

  5.2  Subject to Section 6.1 hereof, if the Executive’s employment shall be terminated for any reason following a Change in
    Control and during the Term, the Company shall pay to the Executive the Executive’s normal post-termination compensation and benefits as such payments become due. Any such post-termination compensation and benefits shall be determined under, and paid
    in accordance with, the Company’s retirement, insurance and other compensation and benefit plans, programs, and arrangements as in effect immediately prior to the date of termination or, if more favorable to the Executive, as in effect immediately
    prior to the occurrence of the first event or circumstance constituting Good Reason.

  6.  Severance Payments.

  6.1  Subject to Section 6.2 and Section 6.3 hereof, if the Executive’s employment is terminated following a Change in Control
    and during the Term either by the Company or by the Executive, other than (a) by the Company for Cause, (b) by reason of death or Disability, or (c) by the Executive without Good Reason, (any such employment termination being hereafter sometimes
    referred to as a “Compensable Termination”), then the Company shall pay the Executive the amounts, and provide the Executive the benefits, described in this Section
    6.1 (“Severance Payments”), in addition to any payments and benefits to which the Executive is entitled under Section 5 hereof. Notwithstanding the foregoing, the
    Executive shall not be eligible to receive any payment or benefit provided for in this Section 6.1 unless the Executive shall have executed a release substantially in the form of Exhibit

        A hereto, and a covenant not to compete and other restrictions substantially in the form of Exhibit B hereto, in each case within sixty (60) days
    following the date of the Compensable Termination (the “Review Period”), and shall not have revoked said release.  The Severance Payments are in lieu of any severance
    benefits that would otherwise be payable or provided pursuant to any severance plan or practice of the Company.

  (i) The Company shall pay the Executive, at the time provided in Section 6.2 below, the Executive’s annual
    bonus for the fiscal year of the Company preceding the fiscal year of the Company in which the Compensable Termination occurs, if unpaid at the time of the Compensable Termination, the amount of such bonus to be determined by the Compensation Committee
    of the Board on a basis no less favorable to the Executive than its bonus determinations

  
    
      

      

    

    Page 3 of 30 pages

    
      

    
      

      

    

  

  

  

  with respect to the Executive prior to the Change in Control, unless the Committee made no bonus determinations with respect
    to the Executive before the Change in Control, in which case on a basis no less favorable to the Executive than its bonus determinations with respect to other executives of comparable rank before the Change in Control.

  (ii) The Company shall pay the Executive, at the time provided in Section 6.2 below, a prorated annual
    bonus for the fiscal year of the Company in which the Compensable Termination occurs, such prorated bonus to be determined by multiplying the “Applicable Average Bonus” as defined below in this subsection (ii) by a fraction, the numerator of which
    shall be the number of days elapsed in such fiscal year through (and including) the date on which the Compensable Termination occurs and the denominator of which shall be the number 365.  For purposes of this Agreement, the “Applicable Average Bonus” means the higher of (A) the average of all annual bonuses (including any deferred bonuses) awarded to the Executive during the thirty-six (36) months immediately
    preceding the Compensable Termination or, if the Executive was employed by the Company for less than thirty-six (36) months before the Compensable Termination, during the period of the Executive’s employment by the Company prior to the Compensable
    Termination (annualizing any bonus awarded for less than a full year of employment), or (B) the average of all annual bonuses (including any deferred bonuses) awarded to the Executive during the three (3) fiscal years of the Company that precede the
    fiscal year in which the Compensable Termination occurs or during the portion of such three fiscal years in which the Executive was employed by the Company (annualizing any bonus awarded for less than a full year of employment), or (C) the average of
    all annual bonuses (including any deferred bonuses) awarded to the Executive during the thirty-six (36) months preceding the date on which the Change in Control occurred or during the portion of such thirty-six (36) month period in which the Executive
    was employed by the Company (annualizing any bonus awarded for less than a full year of employment).

  (iii) The Company shall pay the Executive, at the time provided in Section 6.2 below, a lump sum cash
    payment equal to two (2) times the sum of (x) the Executive’s annual base salary at the rate in effect immediately prior to the Compensable Termination or, if higher, in effect immediately prior to the first occurrence of an event or circumstance
    constituting Good Reason (“Base Salary”), and (y) the Executive’s annual cash bonus target at the rate in effect immediately prior to the Compensable Termination or,
    if higher, in effect immediately prior to the first occurrence of an event or circumstance constituting Good Reason (“Target Bonus”).

  (iv) The Company will pay the Executive for all earned but unused vacation leave at the time of the
    Compensable Termination.

  (v) Subject to the Executive’s timely election and continued eligibility for continuation of coverage
    under the Consolidated Omnibus Budget

  
    
      

      

    

    Page 4 of 30 pages

    
      

    
      

      

    

  

  

  

  Reconciliation Act of 1985, as amended (“COBRA”),

    the Company shall continue the Executive’s participation in the Company’s group medical, dental, vision, and prescription drug coverage at no cost to the Executive and the Executive’s dependents for a period of twenty-four (24) months following the
    date of the Compensable Termination; provided, that, if such continuation is not permitted under the terms of the applicable Company benefit plan or program for all or any portion of such period, would result in the imposition of additional taxes or
    penalties (including, without limitation, under Section 105(h) of the Code), or would otherwise violate any applicable law, then the Company shall instead pay the Executive an additional cash amount per month during the period when such continuation
    would be so prohibited or subject to additional taxes or penalties equal to the total COBRA premium that would have been required to so continue the Executive’s (and the Executive’s dependents’) participation in such medical, dental, vision, and
    prescription drug programs.

  (vi) Any stock options, restricted stock, restricted stock units, performance shares, performance share
    units, or other equity or equity-based awards granted to the Executive on or following the date of this Agreement, but prior to a Change in Control, shall vest in full, with any performance-based vesting requirements deemed achieved at the “target”
    level.  For the avoidance of doubt, any equity or equity-based awards granted to the Executive prior to the date of this Agreement, or following the date of a Change in Control, shall be treated in accordance with their respective terms and conditions.

  6.2  All payments and benefits
      to be made or provided pursuant to subsections (i) through (iv) of Section 6.1 above shall be made, and payments and benefits pursuant to subsection (v) shall commence, within thirty (30) calendar days after the date on which the release attached
      hereto as Exhibit A becomes fully
      effective and irrevocable in accordance with its terms; provided, that, if (x) such thirty (30) calendar day period, together with the Review Period, spans two (2) calendar years, such payments and benefits shall not be made or commence until the
      second (2nd) such calendar year, and (y) if, on the date of the Executive’s Separation from Service the
      Executive is a Specified Employee, and to the extent necessary to avoid the imposition of any additional taxes, interest, or penalties under Section 409A of the Code, such payments shall be made six months and one day after the date of the
      Compensable Termination (or, if earlier, the date of the Executive’s death), with any such payments that would have been made earlier absent this proviso made in a single lump sum on such date.  For purposes of the preceding sentence, a “Specified Employee” means a “specified employee” who is subject to the special rule set forth in subsection (a)(2)(B)(i) of Section 409A of the Code and the regulations
    thereunder (including, without limitation, Treasury Regulation section 1.409A-1(i)) with respect to such payments.

  6.3  In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Executive (i)
    constitute “parachute payments” within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax

  
    
      

      

    

    Page 5 of 30 pages

    
      

    
      

      

    

  

  imposed by Section 4999 of the Code (the “Excise Tax”),
    then Executive’s benefits under this Agreement shall be either

  (i) delivered in full, or

  (ii) delivered as to such lesser extent which would result in no portion of such benefits being subject to
    the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, and local income taxes and the Excise Tax, results in the receipt by Executive on an after-tax basis, of the greatest amount of benefits,
    notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  If a reduction in severance and other benefits constituting “parachute payments” is necessary so that benefits are delivered to a lesser extent,
    reduction will occur in the following order: reduction of cash payments, cancellation of equity awards granted within the twelve (12) month period prior to a “change in control” (as determined under Code Section 280G) that are deemed to have been
    granted contingent upon the change in control (as determined under Code Section 280G), cancellation of accelerated vesting of equity awards, reduction of employee benefits.

  Unless the Company and the Executive otherwise agree in writing, any determination required under this Section shall be made in writing by the
    Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon Executive and the Company for all purposes. 
    For purposes of making the calculations required by this Section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of
    Section 280G and 4999 of the Code.  The Company and the Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section.  The Company shall bear all
    costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section.

  7.  Payments During Dispute. Any
    payments to which the Executive may be entitled under this Agreement, including, without limitation, under Sections 5 and 6 hereof, shall be made forthwith on the applicable date(s) for payment specified in this Agreement.  If for any reason the amount
    of any payment due to the Executive cannot be finally determined on that date, such amount shall be estimated on a good faith basis by the Company and the estimated amount shall be paid no later than ten (10) days after such date.  As soon as
    practicable thereafter, the final determination of the amount due shall be made and any adjustment requiring a payment to or from the Executive shall be made as promptly as practicable.

  8.  No Mitigation. The Company agrees
    that, if the Executive’s employment with the Company terminates during the Term, the Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable or benefits to be provided to the Executive by the Company
    pursuant to Section 6 hereof or any other provision of this Agreement. Further, the amount of any payment or benefit

  
    
      

      

    

    Page 6 of 30 pages

    
      

    
      

      

    

  

  provided for in this Agreement shall not be reduced (a) by any compensation earned by the Executive as the result of employment by another
    employer, (b) by retirement benefits, (c) by offset against any amount claimed to be owed by the Executive to the Company, or (d) otherwise.

  9.  Successors; Binding Agreement.

  9.1  In addition to any obligations imposed by law upon any successor to the Company, the Company will require any successor
    (whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially all of the business and/or assets of the Company to expressly assume and agree to perform the Company’s obligations under this Agreement in the same
    manner and to the same extent that the Company would be required to perform if no such succession had taken place. Failure of the Company to obtain such assumption and agreement prior to the effectiveness of any such succession during the Term shall be
    a breach of this Agreement and shall entitle the Executive to compensation from the Company in the same amount and on the same terms as the Executive would be entitled to hereunder if the Executive were to terminate the Executive’s employment for Good
    Reason after a Change in Control and during the Term, except that, for purposes of implementing the foregoing, the date on which any such succession becomes effective during the Term shall be deemed the date of the Compensable Termination.

  9.2  This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal or legal representatives,
    executors, administrators, successors, heirs, distributees, devisees, and legatees. If the Executive shall die while any amount would still be payable to the Executive hereunder (other than amounts which, by their terms, terminate upon the death of the
    Executive) if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives, or administrators of the Executive’s estate.

  10. Notices. For the purpose of this
    Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail, return receipt requested, postage prepaid,
    addressed, if to the Executive, to the Executive’s most recent address shown on the books and records of the Company at the time notice is given and, if to the Company, to the address set forth below, or to such other address as either party may have
    furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon actual receipt:

  To the Company:

  AngioDynamics, Inc.

  14 Plaza Drive

  Latham, NY 12110

  Attention: Office of the General Counsel

  
    
      

      

    

    Page 7 of 30 pages

    
      

    
      

      

    

  

  11.  Miscellaneous. No provision of
    this Agreement may be modified, waived, or discharged unless such waiver, modification, or discharge is agreed to in writing and signed by the Executive and such officer as may be specifically designated by the Board. No waiver by either party hereto
    at any time of any breach by the other party hereto of, or of any lack of compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at
    the same or at any prior or subsequent time. This Agreement constitutes the entire agreement of the parties concerning the specific subject matter addressed
      by this Agreement and supersedes all prior agreements addressing the terms and conditions contained herein (including, without limitation, the Original Agreement).  The validity, interpretation, construction, and performance of this Agreement
    shall be governed by the laws of the State of New York. All references to sections of the Code or the Exchange Act shall be deemed also to refer to any successor provisions to such sections and to IRS or SEC regulations and official guidance published
    thereunder. Any payments provided for hereunder shall be subject to any applicable withholding required under federal, state, or local law and any additional withholding to which the Executive has agreed. The obligations of the Company and the
    Executive under this Agreement which by their nature may require either partial or total performance after the expiration of the Term (including, without limitation, those under Sections 6 and 7 hereof) shall survive such expiration.

  12.  Validity. The invalidity or
    unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

  13.  Counterparts. This Agreement may
    be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.

  14.  Settlement of Disputes; Arbitration.

  14.1  All claims by the Executive for benefits under this Agreement shall be directed to and determined by the Board and
    shall be in writing. Any denial by the Board of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial and the specific provisions of this Agreement relied upon.
    The Board shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim and shall further allow the Executive to appeal to the Board a decision of the Board within sixty (60) days after notification by the Board
    that the Executive’s claim has been denied.

  14.2  Any further dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by
    arbitration in the Albany, New York metropolitan area in accordance with the employment dispute resolution rules of the American Arbitration Association then in effect. The arbitrator shall have the authority to require that the Company reimburse the
    Executive for the payment of all or any portion of the legal fees and expenses incurred by the Executive in connection with such dispute or

  
    
      

      

    

    Page 8 of 30 pages

    
      

    
      

      

    

  

  controversy. Judgment may be entered on the arbitrator’s award in any court having jurisdiction.

  14.3  The Company agrees to use commercially reasonable efforts to administer this Agreement, and operate any deferred
    compensation plans in which the Executive participates from time to time that are aggregated with this Agreement or with any payment or benefit provided by this Agreement for purposes of Section 409A of the Code (e.g., account balance plans, nonaccount
    balance plans, separation pay plans, and plans that are neither account balance nor nonaccount balance plans), in good faith compliance with Code Section 409A to the extent necessary to avoid inclusion of any amounts of benefits payable hereunder in
    the Executive’s income pursuant to Section 409A(a)(1)(A) of the Code or the imposition of any additional taxes, interest, or penalties under Section 409A of the Code.  Notwithstanding the foregoing, the Executive shall be solely liable for any
    additional taxes, interest, or penalties imposed under Section 409A of the Code, and the Company shall not be required to indemnify the Executive for any such amounts.

  14.4  If there shall be any dispute between the Company and the Executive (i) in the event of any termination of the
    Executive’s employment by the Company, whether such termination was for Cause, or (ii) in the event of any termination of employment by the Executive, whether Good Reason existed, then, unless and until there is a final, non-appealable judgment by a
    court of competent jurisdiction declaring that such termination was for Cause or that the determination by the Executive of the existence of Good Reason was not made in good faith, the Company shall pay all amounts, and provide all benefits, to the
    Executive and/or the Executive’s family or other beneficiaries, as the case may be, that the Company would be required to pay or provide pursuant to Section 6 as though such termination were by the Company without Cause, or by the Executive with Good
    Reason; provided, however, that the Company shall not be required to pay any
    disputed amount pursuant to this paragraph except upon receipt of an undertaking by or on behalf of the Executive to repay all such amounts to which the Executive is ultimately adjudged by such court not to be entitled.

  15.   Definitions. For purposes of
    this Agreement, the following terms shall have the meanings indicated below:

  (A)  “Affiliate” shall have the meaning
    set forth in Rule 12b-2 promulgated under Section 12 of the Exchange Act.

  (B)  “Applicable Average Bonus” shall have
    the meaning set forth in subsection (ii) of Section 6.1.

  (C)  “Base Salary” shall have the
    meaning set forth in subsection (iii) of Section 6.1.

  (D)  “Beneficial Owner” shall have the
    meaning set forth in Rule 13d-3 under the Exchange Act.

  
    
      

      

    

    Page 9 of 30 pages

    
      

    
      

      

    

  

   (E)  “Board” shall mean the Board of
    Directors of the Company.

   (F)  “Cause” for termination by the
    Company of the Executive’s employment shall mean (i) the willful and persistent failure by the Executive to substantially perform the Executive’s duties with the Company as such duties were in effect prior to any change therein constituting Good Reason
    (other than any such failure resulting from the Executive’s incapacity due to physical or mental illness, Disability (as defined in the Employment Agreement, by and between the Executive and the Company, dated as of April 1, 2016, as amended from time
    to time), or any such failure after the occurrence of an event constituting Good Reason for resignation by the Executive) after a written demand for substantial performance is delivered to the Executive by the Board, which demand specifically
    identifies the manner in which the Board believes that the Executive has not substantially performed the Executive’s duties, provided that such failure will constitute Cause only if it remains uncured for more than thirty (30) days following receipt by
    the Executive of such written demand from the Board; (ii) the engaging by the Executive in willful and persistent conduct which is demonstrably and materially injurious to the Company or its subsidiaries, monetarily or otherwise, provided that such
    conduct will constitute Cause only if it remains uncured for more than thirty (30) days following receipt by the Executive of a written demand from the Board to cease such conduct; or (iii) the Executive’s conviction of (a) a felony or (b) a crime
    involving fraud, dishonesty, or moral turpitude. For purposes of clauses (i) and (ii) of this definition, no act, or failure to act, on the Executive’s part shall be deemed “willful” unless done, or omitted to be done, by the Executive not in good
    faith and without reasonable belief that the Executive’s act, or failure to act, was in the best interest of the Company.  The Company shall notify the Executive in a writing that specifically identifies the provision of the Cause definition that
    applies, and must provide the Executive a reasonable period (not less than thirty (30) days) in which to respond and/or cure such alleged grounds to the Board’s satisfaction; and provided further that the Executive shall thereafter be granted the
    opportunity within a reasonable period (not more than thirty (30) days) to appear before the Board, with counsel, to address any such claimed grounds, during which period the Company may not implement such termination. Any purported termination of
    employment by the Company for Cause which does not satisfy the applicable requirements of this Section 15(F) shall be conclusively deemed to be a termination of employment by the Company without Cause for purposes of this Agreement. To the extent that
    this definition of “Cause” is more beneficial to the Executive than any definition of “Cause” in any granting document relating to his stock options, restricted stock units, or performance shares, the Board shall take any such necessary steps to ensure
    that this definition, and not any more restrictive definition contained in any granting document, shall apply.

   (G)  A “Change in Control” shall mean
    that any of the following events has occurred:

  (i) any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company
    representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities,

  
    
      

      

    

    Page 10 of 30 pages

    
      

    
      

      

    

  

  excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (A) of
    paragraph (iii) below; or

  (ii) the following individuals cease for any reason to constitute a  majority of the number of directors
    serving on the Board: individuals who, at the beginning of any period of two (2) consecutive years or less (not including any period prior to the date of this Agreement), constitute the Board and any new director (other than a director whose initial
    assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or nomination for
    election by the Company’s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of such period or whose appointment, election, or nomination for
    election was previously so approved or recommended; or

  (iii) there is consummated a merger or consolidation of the Company or any Subsidiary with any other
    corporation, other than (A) a merger or consolidation which would result in the voting securities of the Company     outstanding immediately prior to such merger or consolidation continuing to     represent (either by remaining outstanding or by being
    converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary, at least sixty
    percent (60%) of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (B) a merger or consolidation effected to implement a
    recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the
    Company’s then outstanding securities; or

  (iv) the shareholders of the Company approve a plan of complete liquidation or dissolution of the Company
    or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets, other than a sale or disposition by the Company of all or substantially all of the Company’s assets to an entity, at
    least sixty percent (60%) of the combined voting power of the voting securities of which are owned by shareholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale.

  (H)  “COBRA” shall have the meaning set
    forth in subsection (v) of Section 6.1.

  (I)  “Code” shall mean the Internal
    Revenue Code of 1986, as amended from time to time.

  
    
      

      

    

    Page 11 of 30 pages

    
      

    
      

      

    

  

  (J)  “Company” shall mean
    AngioDynamics, Inc. and, except in determining under Section 15(G) hereof whether or not any Change in Control of the Company has occurred, shall include any successor to its business and/or assets which assumes and agrees to perform this Agreement by
    operation of law, or otherwise.

  (K)  “Compensable Termination” shall
    have the meaning set forth in Section 6.1.

  (L)  “Disability” shall be deemed the
    reason for the termination by the Company of the Executive’s employment, if, as a result of the Executive’s incapacity due to physical or mental illness, the Executive shall have been absent from the full-time performance of the Executive’s duties with
    the Company for a period of six (6) consecutive months or for six (6) non-consecutive months within any period of twelve (12) consecutive months.

  (M)  “Exchange Act” shall mean the
    Securities Exchange Act of 1934, as amended from time to time.

  (N)  “Executive” shall mean the
    individual named in the first paragraph of this Agreement.

  (O)  “Good Reason” for termination by
    the Executive of the Executive’s employment shall mean the occurrence (without the Executive’s express written consent) after any Change in Control, of any one of the following acts by the Company, or failures by the Company to act, unless, in the case
    of any act or failure to act described in paragraph (i), (iii), (iv), or (vi) below, such act or failure to act is corrected within thirty (30) calendar days after the Company’s receipt of written notice thereof given by the Executive within ninety
    (90) calendar days of such act or failure to act:

  (i) the assignment to the Executive of any duties inconsistent with the Executive’s status or position in
    the Company immediately prior to the Change in Control, or a substantial adverse alteration in the nature, status, or scope of the Executive’s responsibilities or authority from the Executive’s responsibilities or authority immediately prior to the
    Change in Control, or a reduction in the Executive’s title;

  (ii) a reduction by the Company in the Executive’s Base Salary or Target Bonus, in each case as in effect
    on the date of this Agreement or as they may be increased from time to time;

  (iii) a significant reduction in compensation, benefits, or reimbursements provided under any employment,
    compensation, employee benefit, or reimbursement plan or program in which the Executive is a participant which is not replaced with substantially equivalent compensation, benefits, or

  
    
      

      

    

    Page 12 of 30 pages

    
      

    
      

      

    

  

  reimbursements under another plan, program, or arrangement at substantially the same cost (if any) to the Executive;

  (iv) the Company fails to pay or provide any amount or benefit that the Company is obligated to pay or
    provide under this Agreement or any other employment, compensation, benefit, or reimbursement plan, agreement, or arrangement of the Company to which the Executive is a party or in which the Executive participates;

  (v)   the relocation of the Executive’s principal place of employment to a location which increases the
    Executive’s one-way commuting distance by more than forty (40) miles, or the Company’s requiring the Executive to travel on business other than to an extent substantially consistent with the Executive’s business travel obligations prior to the Change
    in Control;

  (vi)   a significant adverse change occurs, whether of a quantitative or qualitative nature, in the
    indemnification protection provided to the Executive for acts and omissions arising out of the Executive’s service on behalf of the Company or any other entity at the request of the Company;

  (vii) a material breach by the Company of any material provision of this Agreement; or

  (viii) the Company fails to obtain the assumption of this Agreement pursuant to Section 9.1.

  The Executive’s right to terminate the Executive’s employment for Good Reason shall not be affected by the Executive’s incapacity due to
    physical or mental illness. The Executive’s continued employment shall not constitute consent to, or a waiver of rights with respect to, any act or failure to act constituting Good Reason hereunder.  To constitute Good Reason, the Executive must
    terminate the Executive’s employment with the Company within ninety (90) calendar days following the date that such event giving rise to Good Reason occurs (or, if later, the date of expiration of any applicable period that the Company has to cure such
    event).  To the extent that this definition of “Good Reason” is more beneficial to Executive than any definition of “Good Reason” in any granting document relating to his stock options, restricted stock units, or performance shares, the Board shall
    take any such necessary steps to ensure that this definition, and not any more restrictive definition contained in any granting document, shall apply.

  (P)  “Person” shall have the meaning
    given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its Subsidiaries, (ii) a trustee or other fiduciary holding securities under an
    employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the shareholders of the

  
    
      

      

    

    Page 13 of 30 pages

    
      

    
      

      

    

  

  Company in substantially the same proportions as their ownership of stock of the Company.

  (Q)  “Potential Change in Control”
    shall be deemed to have occurred if the event set forth in any one of the following paragraphs shall have occurred:

  (i) the Company enters into an agreement, the consummation of which would result in the occurrence of a
    Change in Control;

  (ii) the Company or any Person publicly announces an intention to take or to consider taking actions
    which, if consummated, would constitute a Change in Control;

  (iii) any Person becomes the Beneficial Owner, directly or indirectly, of securities of the Company
    representing fifteen percent (15%) or more of either the then outstanding shares of common stock of the Company or the combined voting power of the Company’s then outstanding securities (not including in the securities beneficially owned by such Person
    any securities acquired directly from the Company or its Affiliates); or

  (iv) the Board adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change
    in Control has occurred.

  (R) “Retirement” shall be deemed the
    reason for the termination by the Executive of the Executive’s employment if such employment is terminated in accordance with the Company’s retirement policy (if any), including early retirement, generally applicable to its salaried employees.

  (S)  “Review Period”
    shall have the meaning set forth in Section 6.1 hereof.

  (T)  “Separation from Service”
    means termination of employment with the Company. However, the Executive shall not be deemed to have a Separation from Service unless such Separation from Service also constitutes a “separation from service” under Section 409A and the regulations
    promulgated thereunder.

  (U)  “Severance Payments” shall have
    the meaning set forth in Section 6.1 hereof.

  (V) “Subsidiary” means a corporation or
    other form of business association of which shares (or other ownership interests) having more than fifty percent (50%) of the voting power are owned or controlled, directly or indirectly, by the Company.

  (W)“Target Bonus” shall have the
    meaning set forth in subsection (iii) of Section 6.1.

  
    
      

      

    

    Page 14 of 30 pages

    
      

    
      

      

    

  

  (X)  “Term” shall mean the period of
    time described in Section 2 hereof (including any extension or continuation described therein).

  

  

  [Remainder of page intentionally left blank. Signature page follows.]

  
    
      

      

    

    Page 15 of 30 pages

    
      

    
      

      

    

  

  IN WITNESS WHEREOF, the parties have executed this Agreement as of the date and year first above written.

  

  

  ANGIODYNAMICS, INC.

  

  

  By: __/s/ Stephen A. Trowbridge_________

  Name: Stephen A. Trowbridge

  Title:   EVP and CFO

  

  

  /s/ James C. Clemmer________________

  James C. Clemmer

  
    
      

      

    

    Page 16 of 30 pages

    
      

    
      

      

    

  

  Exhibit A

  ANGIODYNAMICS, INC.

  RELEASE OF CLAIMS

  This Release of Claims (“Agreement”) is made by and between AngioDynamics, Inc. (the “Company”), and James C. Clemmer (“Executive”).

  WHEREAS, Executive has agreed to enter into a release of claims in favor of the Company upon certain events specified in the Amended and
    Restated Change in Control Agreement by and between Company and Executive, as amended (the “Severance Agreement”).

  NOW THEREFORE, in consideration of the mutual promises made herein, Executive hereby agrees as follows:

  1.  Termination. Executive’s
    employment from the Company terminated on [DATE].

  2.  Confidential Information.
    Executive shall continue to maintain the confidentiality of all confidential and proprietary information of the Company and shall continue to comply with the terms and conditions of the Proprietary Information and Nondisclosure Agreement between
    Executive and the Company (the “Confidentiality Agreement”), as well as Exhibit B to the Severance Agreement. Executive shall return all the Company property and
    confidential and proprietary information in Executive’s possession to the Company on the Effective Date of this Agreement.

  3.  Payment of Salary. Executive
    acknowledges and represents that the Company has paid all salary, wages, bonuses, accrued vacation, commissions, and any and all other benefits due to Executive.

  4.  Release of Claims. Except as set
    forth in the last paragraph of this Section 4, Executive agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company.  Executive, on behalf of himself or herself, and Executive’s
    respective heirs, family members, executors, and assigns, hereby fully and forever releases the Company and its past, present, and future officers, agents, directors, employees, investors, shareholders, administrators, affiliates, divisions,
    subsidiaries, parents, predecessor and successor corporations, and assigns, from, and agrees not to sue or otherwise institute or cause to be instituted any legal or administrative proceedings concerning any claim, duty, obligation, or cause of action
    relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive may possess arising from any omissions, acts, or facts that have occurred up until and including the Effective Date of this Agreement
    including, without limitation:

  
    
      

      

    

    Page 17 of 30 pages

    
      

    
      

      

    

  

  (a) any and all claims relating to or arising from Executive’s employment relationship with the Company and the termination
    of that relationship;

  (b) any and all claims relating to, or arising from, Executive’s right to purchase, or actual purchase of shares of stock of
    the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;

  (c) any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination;
    breach of contract, both express and implied; breach of a covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; negligent or intentional misrepresentation;
    negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; and conversion;

  (d) any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of
    the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1974, and The Worker
    Adjustment and Retraining Notification Act;

  (e) any and all claims for violation of the federal, or any state, constitution;

  (f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; and

  (g) any and all claims for attorneys’ fees and costs.

  Notwithstanding anything to the contrary in this Section 4, the foregoing release does not impair, release, or otherwise modify (A) any
    obligation of the Company to Executive pursuant to any rights to the severance and other benefits payable under the Severance Agreement; or (B) rights to indemnification pursuant to Section 4.5 of the Employment Agreement, by and between the Executive
    and the Company, dated as of April 1, 2016, as amended from time to time (the “Employment Agreement”); or (C) rights to enforce this Agreement; or (D) rights to any vested Long Term Incentives under Section 3.3 of the Employment Agreement in accordance
    with governing award agreement and plan. Executive agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released.

  5.  Acknowledgment of Waiver of Claims under ADEA.
    Executive acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (“ADEA”) and that this waiver and release is knowing and voluntary. Executive and the Company agree that
    this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this Agreement.  Executive acknowledges that the consideration given for this waiver and release Agreement is in addition to
    anything of value to which

  
    
      

      

    

    Page 18 of 30 pages

    
      

    
      

      

    

  

  Executive was already entitled.  Executive further acknowledges that Executive has been advised by this writing that (a) Executive should
    consult with an attorney prior to executing this Agreement; (b) Executive has at least [twenty-one (21)][forty-five (45)] days within which to consider this Agreement; (c) Executive has seven (7) days following the execution of this Agreement to revoke
    the Agreement; (d) this Agreement shall not be effective until the revocation period has expired (provided Executive has not revoked this Agreement); and (e) nothing in this Agreement prevents or precludes Executive from challenging or seeking a
    determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties or costs for doing so, unless specifically authorized by federal law. Any revocation should be in writing and delivered to
    [HR Contact Name] at the Company by close of business on the seventh (7th) day from the date that Executive signs this Agreement.

  6.  No Pending or Future Lawsuits.
    Executive represents that Executive has no lawsuits, claims, or actions pending in Executive’s name, or on behalf of any other person or entity, against the Company or any other person or entity referred to herein. Executive also represents that
    Executive does not intend to bring any claims on Executive’s own behalf or on behalf of any other person or entity against the Company or any other person or entity referred to herein.

  7.  Application for Employment.
    Executive understands and agrees that, as a condition of this Agreement, Executive shall not be entitled to any employment with the Company, its subsidiaries, or any successor, and Executive hereby waives any right, or alleged right, of employment or
    re-employment with the Company.

  8.  No Cooperation. Executive agrees
    that Executive will not counsel or assist any attorneys or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against the Company and/or any officer, director,
    employee, agent, representative, shareholder, or attorney of the Company, unless under a subpoena or other court order to do so.

  9.  Cooperation with Company.
    Executive agrees to cooperate, at the request of the Company, in the defense and/or prosecution of any charges, claims, investigations (internal or external), administrative proceedings, and/or lawsuits relating to matters occurring during or relating
    to Executive’s period of employment about which Executive may have relevant information. Executive shall further reasonably cooperate with regard to the transition of Executive’s job duties and business relationships. Executive agrees to respond to
    reasonable requests for information from the Company in a timely manner.

  10.  No Admission of Liability. No
    action taken by the Company, either previously or in connection with this Agreement shall be deemed or construed to be (a) an admission of the truth or falsity of any claims heretofore made or (b) an acknowledgment or admission by the Company of any
    fault or liability whatsoever to Executive or to any third party.

  11.  Costs. Executive shall bear
    Executive’s own costs, expert fees, attorneys’ fees, and other fees incurred in connection with executing this Agreement.

  
    
      

      

    

    Page 19 of 30 pages

    
      

    
      

      

    

  

  12.  Authority. Executive represents
    and warrants that Executive has the capacity to act on Executive’s own behalf and on behalf of all who might claim through Executive to bind them to the terms and conditions of this Agreement.

  13.  No Representations. Executive
    represents that Executive has had the opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the provisions of this Agreement.  Executive has not relied upon any representations or statements made by the
    Company which are not specifically set forth in this Agreement.

  14.  Severability. In the event that
    any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision.

  15.  Entire Agreement. This Agreement,
    along with the Confidentiality Agreement, the Severance Agreement, and Executive’s written equity compensation agreements with the Company, represents the entire agreement and understanding between the Company and Executive concerning Executive’s
    separation from the Company.

  16.  No Oral Modification. This
    Agreement may only be amended in writing signed by Executive and a duly authorized officer of the Company (other than Executive).

  17.  Governing Law. This Agreement
    shall be governed by the internal substantive laws, but not the choice of law rules, of the State of New York.

  18. Effective Date. Executive has
    seven (7) days after Executive signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Executive signed this Agreement (“Effective Date”), provided that Executive has not timely revoked this Agreement.

  19.  Voluntary Execution of Agreement.
    This Agreement is executed voluntarily and without any duress or undue influence on the part of Executive, with the full intent of releasing all claims. Executive acknowledges that:

  (a) Executive has read this Agreement;

  (b) Executive had the opportunity of being represented in the preparation, negotiation, and execution of this Agreement by
    legal counsel of Executive’s own choice or Executive has voluntarily declined to seek such counsel;

  (c) Executive understands the terms and consequences of this Agreement and of the releases it contains;

  (d) Executive is fully aware of the legal and binding effect of this Agreement.

  
    
      

      

    

    Page 20 of 30 pages

    
      

    
      

      

    

  

  IN WITNESS WHEREOF, Executive has have executed this Agreement on the date set forth below.

  Dated:  [MONTH], 20___

  By:      __________________________

  

  James C. Clemmer

  
    
      

      

    

    Page 21 of 30 pages

    
      

    
      

      

    

  

  Exhibit B

  ANGIODYNAMICS, INC.

  NON-COMPETITION AND NON-SOLICITATION AGREEMENT

  This Non-Competition and Non-Solicitation Agreement (“Agreement”) is made by and between AngioDynamics, Inc. (the “Company”), and James C.
    Clemmer (“Executive”).

  WHEREAS, Executive has agreed to enter into a non-competition and non-solicitation agreement in favor of the Company upon certain events
    specified in the Amended and Restated Change in Control Agreement by and between the Company and Executive, as amended (the “Severance Agreement”); and

  WHEREAS, in consideration for the Company’s promises and covenants contained in the Severance Agreement, Executive agrees to be bound by the
    terms of this Agreement.

  NOW THEREFORE, in consideration of the mutual promises made herein and in the Severance Agreement, Executive and the Company hereby agree as
    follows:

  
    	
            1.

          	
            Terms used in this Agreement:

          
	 	 
	
            a.

          	
            AngioDynamics means AngioDynamics, Inc., its successors or
              assigns, and any of their existing and future divisions, subsidiaries, and affiliates.

          
	 	 
	
            b.

          	
            Confidential Information means all trade secrets, proprietary
              information, know-how, and confidential information disclosed to Executive or known by Executive as a result of Executive’s employment by AngioDynamics, not generally known in the trade or industry in which AngioDynamics is engaged, about
              AngioDynamics’ business operations, customers, suppliers, products, processes, machines, systems, and services, including research, development, manufacturing, purchasing, finance, data processing, engineering, marketing, designs, concepts,
              know-how, merchandising, and selling, and corresponding information about the products, processes, machines, and services of AngioDynamics, acquired by Executive during Executive’s employment by 

          

    

    

    
      
        

        

      

      Page 22 of 30 pages

      
        

      
        

        

      

    

    

    

    	 	
            AngioDynamics. The fact that information is not patentable or copyrightable shall not affect its status as Confidential Information.

          
	 	 
	
            c.

          	
            Conflicting Product means any product, process, machine, or
              service of any person or organization other than AngioDynamics, whether now existing or hereafter developed: (a) which is identical to, substantially the same as, an adequate substitute for, resembles, or competes with a product, process,
              machine, system, or service upon or with which Executive worked during Executive’s term of employment with AngioDynamics or about which Executive acquired Confidential Information; or (b) whose use or marketability could be enhanced by
              application to it of Confidential Information to which Executive had access during Executive’s employment with AngioDynamics; or (c) which is (or could reasonably be anticipated to be) marketed

          

  

  

  
    
      

      

    

    Page 23 of 30 pages

    
      

    
      

      

    

  

  
    	 	
            or distributed in such a manner and in such a geographic area as to actually compete with such a product, process, machine, or service of AngioDynamics.

          
	 	 
	
            d.

          	
            Conflicting Organization means any person or organization, which
              is now or hereafter engaged directly or indirectly in research on or the acquisition, development, production, distribution, marketing, providing, or selling of a Conflicting Product.

          
	 	 
	
            e.

          	
            Terms not defined herein shall have the meaning ascribed to such terms in the Severance Agreement.

          
	 	 
	
            2.

          	
            Non-Competition.

          
	 	 
	
            a.

          	
            For a period of twenty four (24) months after termination of Executive’s employment with AngioDynamics pursuant to the Severance Agreement, Executive
              will not render services, directly or indirectly, to any Conflicting Organization.

          
	 	 
	 	
            However, notwithstanding the foregoing, Executive understands that he/she may work for a Conflicting Organization whose business is diversified, provided
              Executive’s work for the Conflicting Organization does not involve selling, managing, overseeing, developing, creating, promoting, servicing, involvement in the financing and/or accounting of, or other responsibility for any Conflicting
              Product on which Executive worked or gained Confidential Information during the last two (2) years of Executive’s employment with AngioDynamics. Prior to accepting such employment, the Conflicting Organization and Executive must provide
              written assurances reasonably satisfactory to AngioDynamics (as determined in good 

          

    

    

    
      
        

        

      

      Page 24 of 30 pages

      
        

      
        

        

      

    

    

    

    	 	
            faith), that Executive will not render services, directly or indirectly, in connection with any Conflicting Product on which Executive worked or gained
              Confidential Information during the last two (2) years of Executive’s employment with AngioDynamics and that necessary safeguards have been put in place to ensure that this does not happen.  This section shall be construed in a manner to give
              effect to the restrictions contained herein to the maximum extent permitted by applicable law.

          
	 	 
	
            b.

          	
            The restrictions set forth in Section 2(a) apply in the United States and in any foreign country or foreign territory where AngioDynamics produces,
              sells, or markets its goods and services.

          
	 	 
	
            3.

          	
            Non-Solicitation.

          
	 	 
	
            a.

          	
            Business Relations. Executive agrees that for a
              period of twenty four (24) months after the termination of Executive’s employment with AngioDynamics pursuant to the Severance Agreement, Executive will not solicit, induce, attempt to induce, appropriate, direct, or assist another to
              appropriate or direct, or provide any services to any current customer, supplier, licensee, or other business relation (defined as any customer, supplier, licensee, or other business relation of AngioDynamics with whom Executive had dealings
              and/or for whom Executive performed services at any time during the last two (2) years of Executive’s employment with AngioDynamics) to

          

  

  
    
      

      

    

    Page 25 of 30 pages

    
      

    
      

      

    

  

  
    	 	
            cease doing business with AngioDynamics (including, without limitation, making any negative statements or communications concerning AngioDynamics or any
              of its directors, officers, or employees).

          
	 	 
	
            b.

          	
            Employees. Executive agrees that for a period of
              twenty four (24) months after the termination of Executive’s employment with AngioDynamics pursuant to the Severance Agreement, Executive will not solicit, interfere with, encourage, endeavor, or engage in discussions with any employee or
              independent contractor of AngioDynamics for the purpose of (or with a view toward) having such employee or independent contractor leave the employment (or independent contractor assignment) of AngioDynamics for any reason, including leaving
              to render services to any Conflicting Organization.

          
	 	 
	
            4.

          	
            Mutual Non-Disparagement:  Executive will not
              disparage any released party (as specified in Exhibit A to the Severance Agreement) (each, a “Released Party”) or otherwise take any action which could
              reasonably be expected to adversely affect the personal or professional reputation of any Released Party.  AngioDynamics, Inc. (or its successor) or the ultimate parent company of AngioDynamics, Inc. (if AngioDynamics, Inc. is a subsidiary of
              another entity on Executive’s termination date) shall instruct the members of its Board of Directors and its executive officers to not disparage Executive or otherwise take any action which could reasonably be expected to adversely affect the
              personal or professional reputation of Executive. Notwithstanding the foregoing, in no 

          

    

    

    
      
        

        

      

      Page 26 of 30 pages

      
        

      
        

        

      

    

    

    

    	 	
            event will any truthful, legally required disclosure or action be deemed to violate this Section, regardless of the content of such disclosure or the
              nature of such action.

          
	
            5.

          	
            Miscellaneous.

          
	 	 
	
            a.

          	
            This Agreement is personal to Executive and may not be assigned by Executive. This Agreement shall inure to the benefit of AngioDynamics, its successors,
              and assigns.

          
	 	 
	
            b.

          	
            Any dispute arising under or in connection with this Agreement or related to any matter which is the subject of this Agreement shall be subject to the
              exclusive jurisdiction of the state and federal courts located in New York, and this Agreement shall be construed under and according to the laws of the State of New York, without regard to its conflict of laws rules.

          
	 	 
	
            c.

          	
            Executive acknowledges that any breach or threatened breach of this Agreement by Executive will cause AngioDynamics material and irreparable injury and
              monetary damages may not be an adequate remedy for such injury.  In the event of a breach or threatened breach of this Agreement, AngioDynamics may pursue any remedies at law or equity available to it, including injunctive relief. 
              Notwithstanding anything contained in this Agreement to the contrary, in addition to any remedies available to AngioDynamics (and not in exclusion of any such remedies) in the event of a breach of this Agreement, Executive shall be required
              to remit to AngioDynamics any severance payments paid to Executive by AngioDynamics pursuant to the Severance Agreement.

          

  

  
    
      

      

    

    Page 27 of 30 pages

    
      

    
      

      

    

  

  
    	
            d.

          	
            If any provision of this Agreement is held by any court of competent jurisdiction to be illegal, overly broad, invalid, or otherwise unenforceable in
              duration, geographical coverage, substantive scope, or otherwise, then this Agreement will be deemed amended to the extent necessary to render the otherwise unenforceable provision, and the rest of the Agreement, valid and enforceable.  If a
              court declines to amend this Agreement as provided herein, the invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of the remaining provisions, which shall be enforced as if the
              offending provision had not been included in this Agreement.

          
	 	 
	
            e.

          	
            In the event of a violation of this Agreement, the time limitations set forth in this Agreement shall be extended for a period of time equal to the
              period of time during which such breach occurs, and, in the event AngioDynamics is required to seek relief from such breach before any court, board, or other tribunal, then the time limitation shall be extended for a period of time equal to
              the pendency of such proceedings, including all appeals.

          
	 	 
	
            f.

          	
            For twenty-four (24) months following the termination of Executive’s employment with AngioDynamics pursuant to the Severance Agreement, Executive agrees
              to show this Agreement to any prospective employer before Executive directly or indirectly owns, manages, operates, controls, becomes employed by, becomes a shareholder of, becomes a director of, becomes an officer of, participates in,
              contracts with, or becomes connected in any capacity or in any manner with such person or entity during any restrictive period provided in this Agreement.  Executive also agrees to 

          

    

    

    
      
        

        

      

      Page 28 of 30 pages

      
        

      
        

        

      

    

    

    

    	 	
            inform AngioDynamics at the time Executive gives notice of separation from employment, of the identity of Executive’s new employer and Executive’s new
              job title and responsibilities.

          
	 	 
	
            g.

          	
            EXECUTIVE ACKNOWLEDGES HAVING READ, EXECUTED, AND RECEIVED A COPY OF THIS AGREEMENT, UNDERSTANDS HIS/HER OBLIGATIONS UNDER THIS AGREEMENT, SIGNS IT
              VOLUNTARILY, INTENDS TO BE LEGALLY BOUND BY THIS AGREEMENT, AND AGREES THAT WITH RESPECT TO THE SUBJECT MATTER HEREOF IT IS EXECUTIVE’S ENTIRE AGREEMENT WITH ANGIODYNAMICS AND SUPERSEDES ANY PREVIOUS ORAL OR WRITTEN COMMUNICATIONS,
              REPRESENTATIONS, UNDERSTANDINGS, OR AGREEMENTS WITH ANGIODYNAMICS OR ANY OF ITS OFFICIALS OR REPRESENTATIVES.

          

    

    

    Executive further acknowledges that the restrictions imposed by this Agreement are necessary and reasonable to protect AngioDynamics’ business interests and will not preclude Executive from becoming gainfully employed in a suitable capacity following
    the termination of Executive’s employment with AngioDynamics given Executive’s general knowledge and experience.

  [Signature Page Follows]

  
    
      

      

    

    Page 29 of 30 pages

    
      

    
      

      

    

  

  

  

  IN WITNESS WHEREOF, Executive and AngioDynamics have hereunto affixed their signatures, this _____________ day of ______________________ 20
    ______.

  ___________________________________________

  Executive

  AngioDynamics, Inc.

  ___________________________________________

  Signature

  ___________________________________________

  Print Name

  ___________________________________________

  Title

  

  

  

  

  
    

    

  

  Page 30 of 30 pages

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]